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"If you make listening and observation your occupation, 
you will gain much more than you can by talk.” 





Background: In complex cancer-related pain in imminently dying patients, even high doses 
of ordinary opioids may have an insufficient effect. The addition of low-dose methadone to 
another ongoing opioid has been proposed as a treatment option. The aims of this thesis were 
to study different aspects of low-dose add-on methadone to another ongoing opioid in 
specialized palliative care in Sweden.  
Patients, methods and results: In Study I, the medical records of 80 patients prescribed low-
dose add-on peroral methadone to an ongoing opioid were assessed retrospectively. Eighty 
percent reached better pain control. Delirium and sedation increased near the end of life, but 
no serious adverse events were registered. In Study II, data on 4780 patients from 60 
specialized palliative care units were analyzed. Methadone was safely prescribed, even in 
home care, to 8.6% of the patients (n=410), 96% of whom received it as a low-dose add-on 
for complex pain. In total, 94% were reported to benefit. Study III was a qualitative study to 
explore different aspects of methadone use. Semi-structured interviews were conducted with 
30 physicians in specialized palliative care and pain medicine. Attitudes to methadone were 
reported not to affect its use as an analgesic and methadone was reported to achieve a best 
effect in situations of long-term opioid use with insufficient pain improvement and cases with 
central sensitization. Pain from skeletal metastases in the spine or pelvis were described to 
benefit particularly well. Cancer of the prostate, breast, kidney, pancreas, and sarcoma were 
reported as typical benefitting diagnoses. In Study IV, the daily symptoms of 93 imminently 
dying patients prescribed pain management via continuous subcutaneous infusion were 
followed. Improvement of pain, but unchanged prevalence of delirium, regardless of age, was 
seen in all patients. Low-dose add-on methadone was safely used in the patients with the 
highest initial pain. The daily median start dose of methadone in all studies was reported as 5 
mg, increasing to a maximum of 20 mg.  
Discussion: Studies I-IV report that dying patients with complex cancer-related pain may 
obtain improved pain control from low-dose add-on methadone to another ongoing opioid, 
with limited side-effects. Attitudes to methadone seem not to be an obstacle to its use. 
Continuous subcutaneous infusion of opioids, including low-dose methadone, can effectively 
and safely reduce pain in the imminently dying patient without an increase of delirium, 
regardless of age. Overall, low-dose add-on methadone may be considered a valuable tool for 
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1 PERSONAL INTRODUCTION 
As a newly trained physician around the turn of the millennium, I had a hard time deciding 
the direction that my career should take, and I worked as an anesthesiologist, pediatrician, 
and internist. For some time, I also worked as physician in the archipelago of northernmost 
Norway. Back home, by chance, I started working with people dying of cancer who were 
cared for in their own homes, i.e., in specialized palliative home care. The work was very 
challenging and combined many exciting medical disciplines such as pharmacology, 
physiology, psychiatry and communication skills. Above all, together with the team, I was 
able to make a difference for these suffering patients and their families, who often felt 
abandoned by the rest of the healthcare system. The job felt very meaningful. I had found my 
medical direction, and I wanted to continue working with these patients. Through the 
specialty of geriatrics, I became a specialist in palliative medicine.  
Cancer-related pain is usually a symptom that must be alleviated before one can even 
consider helping patients with their other problems. Supportive talks are not an option when 
the patient is in severe pain that takes all his or her attention.  
Still, pain can be different even in cancer. Working in a palliative care service at Nacka 
hospital in the middle of the 00s I found the cancer-related pain in some patients harder to 
treat than usual, the regular drugs did not help. In complex cases where I struggled to provide 
good analgesia, there was always the possibility that pain relief was difficult to reach because 
of existential, psychological, social, or other factors. Sometimes, however, I felt this could 
not be the only explanation. 
In connection with some of these more complex pain situations, I had contact with the pain 
clinic at Södersjukhuset hospital. They sometimes recommended the addition of a low dose 
of methadone to the patients’ already ongoing opioid. In some cases, this regimen did not 
help, in other cases it seemed to contribute to a much better analgesia.  
When I started working at Stockholm Sjukhem in 2011, it turned out that the physicians there 
had, since the middle of the 00s, following the publication of Mercadante et al., also used low 
doses of methadone in a similar way [1]. My curiosity was thus aroused. I wanted to find out 
more about the use of low-dose add-on methadone, but the existing literature on the subject 
was limited.  
Thanks to the unique expertise in palliative research available at the research department at 
Stockholm Sjukhem, together with a warm and welcoming attitude, I had the opportunity to 
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A top priority for both dying patients and their families is a pain-free status at the end of life 
[2]. In its definition of palliative care the WHO emphasizes the importance of identifying 
physical and other symptoms in order to prevent and relieve suffering [3]. The adequate 
control of pain and other symptoms in patients with life-threatening diseases, resulting in 
improved quality-of-life for both patients and their families, is important [3]. To achieve this 
goal, effective treatment options are needed.  
Opioids are the basis for the relief of moderate to severe cancer-related pain [4]. Sometimes 
rotation from one opioid to another can contribute favorably to further improved pain relief 
[5]. Methadone is an opioid that, due to its unique pharmacodynamic properties, is 
occasionally turned to for managing complex cancer-related pain. Its complex pharmacology 
presupposes knowledgeable and experienced users, familiar with the drug. This can be a 
barrier to its use and therefore safe alternative methods, to take advantage of the properties of 
methadone, would be of great value in achieving better pain relief for some patients. 
This literature review aims at providing a background for understanding the mechanisms and 
effects behind the novel use of low-dose methadone as an add-on to other regular opioids for 
pain management in end-of-life cancer patients.  
2.1 CANCER-RELATED PAIN 
Management of pain is a common clinical problem in cancer patients. In a review of 122 
articles van den Beuken - van Everdingen et al. reported that cancer-pain prevalence, despite 
treatment, was 40% after curative treatment, 55% during anticancer treatment, 66% in 
advanced, metastatic, or terminal disease and 51% in all cancer stages. Thus indicating that 
pain treatment for cancer patients remains suboptimal [6].  
Moreover, untreated pain has been reported to accelerate death by limiting mobility, 
increasing physiological stress, and increasing the risk of complications, e.g., pneumonia and 
thromboembolism [7, 8].  Nevertheless, pain management in palliative care patients with 
advanced cancer has improved over the last few years due to a better understanding of pain 
mechanisms, new guidelines, and attempts to tailor a mechanism-based treatment targeting 
each pain component (e.g., nociceptive somatic, nociceptive inflammatory, neuropathic pain 
etc.) [4, 6, 9-11]. 
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2.1.1 Pain, definitions 
In July 2020, the International Association for the Study of Pain (IASP) introduced a new 
definition of pain, replacing the previous one that had been unchanged since 1979 [12]. More 
than before, the new definition emphasizes the individual's own experience of pain.   
Pain: an unpleasant sensory and emotional experience associated with, or resembling that 
associated with, actual or potential tissue damage. 
Six key notes are associated with this definition: 
• Pain is always a personal experience that is influenced to varying degrees by 
biological, psychological, and social factors. 
• Pain and nociception are different phenomena. Pain cannot be inferred solely from 
activity in sensory neurons. 
• Through their life experiences, individuals learn the concept of pain. 
• A person’s report of an experience as pain should be respected. 
• Although pain usually serves an adaptive role, it may have adverse effects on 
function and social and psychological well-being. 
• Verbal description is only one of several behaviors to express pain; an inability to 
communicate does not negate the possibility that a human or a nonhuman animal 
experiences pain. 
 
Other essential definitions are:  
Nociceptive pain: pain that arises from actual or threatened damage to non-neural tissue and 
is due to the activation of nociceptors. 
Neuropathic pain: pain caused by a lesion or disease of the somatosensory nervous system 
2.1.2 Pain assessment at the end of life without self-reporting 
In most settings pain intensity is assessed with, for example, a visual analogue scale (VAS) or 
a numeric rating scale (NRS) [13]. However, as their disease progresses, the dying patient's 
ability to verbalize pain deteriorates. The delirium prevalence in cancer patients in a palliative 
setting is reported to be between 13 and 42% and may increase to 88% at the end of life [14-
17]. The absence of reported pain does not necessarily mean that the patient is not 
experiencing pain or that the pain has resolved. Therefore, when assessing pain in dying 
patients who have had pain in the past and for whom it has become more difficult to 




Due to the practical difficulties of studying pain in imminently dying patients, this is an 
under-researched area, a gap in the knowledge that needs to be covered.  
2.1.3 Complex pain 
The term complex pain in this text, although not an official term, refers to pain that is 
refractory or partially refractory to first-line treatments, but often involves both nociceptive 
and neuropathic pain components and where central sensitization plays an important role. 
Examples of first-line treatments are opioids and/or COX-inhibitors for nociceptive 
continuous visceral cancer-related pain and gabapentin and/or amitriptyline for neuropathic 
cancer-related pain [19, 20]. 
Moreover, there are novel treatments emerging in regards to nociceptive inflammatory and/or 
neuropathic pain, e.g., a Swedish group reported that supplementation with vitamin D may 
reduce opioid consumption in patients with cancer-related pain and concomitant vitamin D 
deficiency [21-23].  
Opioids are often effective as first line treatments in nociceptive cancer-related pain but have 
variable and often inadequate effects on neuropathic and mixed nociceptive-neuropathic pain. 
For the treatment of neuropathic pain components in cancer, which partially differs from the 
treatment of neuropathic pain in non-cancer conditions, opioids are often combined with 
tricyclic antidepressants, gabapentin or pregabalin and/or serotonin-noradrenaline reuptake 
inhibitors as well as with steroids and non-steroid anti-inflammatory drugs in cases with 
inflammatory components [24].  
2.1.4 Central sensitization 
Complex pain is often due to a combination of nociceptive and neuropathic pain mechanisms 
and management often remains a challenge [25-27]. Central sensitization can cause an 
accelerated state of pain despite no progressive tissue damage and is defined by IASP as an 
increased responsiveness of nociceptive neurons in the central nervous system to their normal 
or subthreshold afferent input [12, 28-30].  
This central sensitization, which is associated with a decreased opioid sensitivity, is partly 
mediated by activation of the N-methyl-D-aspartate (NMDA) receptor [31, 32]. There is also 
evidence that NMDA receptors are involved in the development of allodynia, hyperalgesia, 
opioid tolerance and opioid resistant neuropathic pain [33]. 
Recent research has proposed the possibility that neurons can fine-tune NMDA receptor 
signaling by shifting the ratio of the expressed four subunits that compose NMDA receptors, 
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so called GluN subunits [34]. Thus, the selective expression of NMDA receptors containing 
distinct GluN isoforms provides new opportunities to study functional properties relevant to 
neuronal receptors [34].  
2.1.5 Opioid rotation and opioid combination therapy 
Rotation to another opioid is an option when the first-line opioid provides inadequate pain-
relief or intolerable adverse effects. The success rate has varied from 50-80%, but only when 
rotating to methadone a reduction in morphine equivalent daily doses (MEDD) could be seen, 
indicating that methadone has properties that differ from other opioids [35-37]. An additional 
important explanation for why opioid rotation can be successful is that there often may exist a 
cross-tolerance between opioids, meaning that the new opioid has a better analgesic effect 
than expected from equianalgesic tables. Therefore, a lower start dose is often chosen with 
reduced adverse effects [38]. 
An example of a clinical situation where morphine adverse effects may occur due to 
accumulation of the renally eliminated morphine metabolites morphine-3-glucuronide (M3G) 
and morphine-6-glucuronide (M6G) is in progressive terminal renal impairment at the end of 
life. M6G contributes to analgesia but M3G is more associated with central adverse adverse 
effects, such as delirium and myoclonus, and the development of opioid tolerance [39]. 
Rotation from morphine to oxycodone, fentanyl, hydromorphone or methadone may then 
improve the analgesic effect and reduce adverse effects, even in the severely ill patient [40].   
However, a review by Schuster et al. in 2018 confirmed the stated findings in the Cochrane 
review from 2004 that, although widely practiced, robust evidence for the benefit of opioid 
rotation is still lacking, mainly due to methodological limitations [41, 42].  
Combining two opioids is another theoretical option for improving analgesia aimed at 
limiting the development of opioid tolerance and decreasing opioid adverse effects. The 
rationale comes from laboratory research that reported an additive analgesic effect when 
methadone was combined with oxycodone and fentanyl, while combination with morphine or 
diamorphine revealed even a synergistic effect [43]. 
Overall, the evidence concerning opioid combination therapy is limited and there is so far, 





2.1.6 Opioid-induced hyperalgesia (OIH) 
Opioids that are intended to abolish pain can sometimes unexpectedly aggravate it instead, 
particularly in cases of rapid opioid dose escalation. In particular, opioids generating active 
metabolites, such as morphine-3-glucurionide, have been associated with OIH  [45, 46]. 
NMDA receptors are thought to play a role and the addition of NMDA-receptor inhibiting 
drugs, together with a reduction of the opioid dose, can significantly diminish the worsened 
state [47-54]. 
2.2 METHADONE 
The opioid methadone was synthesized by Hoechst in Germany in 1938, initially in the 
search for a spasmolytic drug, and its analgesic properties were not primarily appreciated at 
the time. The name derives from fragments of its chemical name: 6-dimethylamino-4,4-
diphenyl-3-heptanone [55]. Methadone is used for methadone maintenance therapy (MMT) 
of both opioid use disorder and chronic pain patients and is recognized as an important 
analgesic drug [56, 57].  
2.2.1 Pharmacodynamics 
Methadone has unique analgesic properties. It stimulates both regular mu, kappa and delta 
opioid receptors, has N-methyl-D-aspartate (NMDA) receptor inhibiting effects and affects 
the reuptake of serotonin and norepinephrine in the pain modulating descending tracts in the 
medulla [31, 58-60]. The R-isomer of methadone has opioid receptor affinity, and the S- and 
R-isomers have comparable NMDA receptor antagonism [60]. It is the S-isomer of 
methadone that is a potent inhibitor of serotonin and norepinephrine uptake [60]. Methadone 
binds to the NMDA receptor to the same degree as ketamine [60]. 
2.2.2 Pharmacokinetics 
Methadone is a lipophilic opioid with high oral bioavailability, generally over 85%. The 
recommended parenteral dose is usually, not least because of safety reasons, 50-80% of the 
oral dose [60, 61]. By analogy, the established recommendation for conversion from 
parenteral to oral methadone has been 1:2. However, recent research suggests that the 
analgesic effect may be maintained, while the risk of drug-related adverse reactions such as 
drowsiness and myoclonus may be reduced, with a more conservative parenteral to oral 
conversion ratio of 1:1.2 [62].  
Oral administration is followed by rapid gastrointestinal absorption with measurable plasma 
levels at 30 minutes. The peak plasma levels after a single oral dose occur at four hours and 
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begin to decline 24 hours after dosing [60]. Methadone is metabolized in the liver mainly via 
CYP3A4, and with a lesser involvement of CYP2D6 and CYP2C8, and 20-50% is excreted 
via the kidneys, the rest via feces [60, 63-65]. In anuric patients, elimination is exclusively 
via the fecal route. Dosage adjustment is not required in renal insufficiency, nor in 
hemodialysis. Additionally, methadone does not appear to produce active, potentially toxic 
metabolites [60, 65].  
Racemic methadone has a biphasic elimination with a rapid initial distribution phase within 
2-3 hours, followed by a prolonged terminal elimination phase, the half-life varying greatly in 
length from 5 to 130 hours with a mean of approximately 20-35 hours [60, 66]. The biphasic 
elimination contributes to the fact that despite the long half-life, the drug's analgesic effect at 
the start of the treatment is only 5-6 hours and with longer treatment the effect lasts for 8-12 
hours [67]. The half-life is shorter in subjects on chronic methadone therapy, probably due to 
autoinduction of methadone’s metabolism. It is generally considered that a steady state is 
reached after 3 to 5 times the half-life for a drug, after regular dosing is started. It therefore 
may take from one day to several weeks to reach steady‐state levels of methadone [66].  
2.2.3 Methadone as a long-acting agent 
Methadone is considered a long-acting agent [68]. Before the oral slow-release preparations 
of opioids were introduced in the late 1980s, methadone was occasionally used for long-term 
relief of opioid-sensitive nociceptive pain when a more long-lasting effect was wanted. 
Because a primary µ-receptor effect was then sought, relatively high doses were required. A 
standard dosing schedule was 10 mg up to every 4-5 hours for the first 24 hours before 
switching to dosing three times a day [69]. During the first few days of treatment, the 
duration of analgesia did not differ significantly between morphine and methadone but 
became more pronounced with long-term treatment [70]. 
2.2.4 Methadone as an analgesic in cancer-related pain 
Today, methadone is internationally recommended as a second-line opioid in the 
management of cancer-related pain [71]. It is predominantly used for switching from another 
opioid to improve the balance between analgesia and adverse effects [71]. The combination 
of opioid agonism, no active metabolites, as well as NMDA receptor inhibition, could 
potentially provide analgesic effects with fewer adverse effects than other opioids [67]. 
However, several reviews have reported high-dose methadone in cancer-related pain to be 
similar or better in effect compared with both morphine and transdermal fentanyl, but with a 




dose escalation of methadone over time is usually limited [71, 73, 75]. Despite some evidence 
for an analgesic effect in chronic neuropathic pain [76], the Cochrane reviews from 2017 
concerning methadone for cancer pain and neuropathic pain in adults could not draw any 
final conclusions regarding differences in efficacy or safety between methadone and a 
placebo, other opioids, or other treatments [77]. This was mainly due to small and low-
qualitative studies.  
Methadone is often considered as an alternative or complement to other opioids when they do 
not have the expected effect, which can often be due to the fact that the pain is not purely 
sensitive to µ-receptors, and other mechanisms also need to be taken into account, such as 
inhibiting NMDA receptors [71].  
2.2.5 Practical obstacles 
Despite its reported unique properties, many clinicians are reluctant to use methadone 
because of its complex pharmacokinetics and numerous drug interactions [66].  
In some patients, even low doses of methadone can result in an opioid overdose [78]. It is 
known that pain stimulates the respiratory drive in the respiratory center in the brain stem [79, 
80]. If methadone is given for pain that has insufficiently responded to regular opioids but 
responds well to the partially unique properties of methadone, probably particularly NMDA 
receptor inhibition, it may contribute rapidly to better pain relief. If good pain relief is 
obtained and the stimulating effect of the pain on the respiratory tract hence decreases, the 
risk of overdose with subsequent respiratory depression increases [79, 80]. It seems that even 
low doses of add-on methadone can have this effect and may thus contribute to a relative 
opioid overdose when combined with high doses of common opioids (such as morphine, 
oxycodone, hydromorphone, or fentanyl). A similar effect may be seen in individuals who are 
methadone naïve because they metabolize methadone more slowly than patients using 
methadone regularly [61]. 
Furthermore, conversion from another opioid to methadone demands caution since the 
potency ratio from morphine to methadone varies and can be difficult to predict, exemplified 
by Ripamonti et al. who found a conversion dose ratio from 2.5:1 to 14.3:1 in patients with 
advanced cancer taking a pre-rotation MEDD of 145 mg opioid per day [81]. However, 
conversion ratios are in general dose-dependendent in relation to MEDD and there are 
practically useful conversion tables that can be applied. In all studies in this thesis, MEDD 
were calculated according to guidelines from the MD Anderson Hospital (Houston, TX) [82]. 
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Clinicians may also hesitate to prescribe methadone as an analgesic due to the social stigma 
surrounding its use in the treatment of heroin (diamorphine) abuse [83].  
2.2.6 Adverse effects of methadone 
Mu-receptor related adverse effects of opioids are equally common with methadone, 
including constipation, OIBD (opioid induced bowel dysfunction), delirium, sedation, nausea, 
hypotension, miosis, and respiratory depression. [65, 67, 71, 72, 77, 84].  
Long-term opioid treatment may also have endocrine effects. Rhodin et al. compared chronic 
pain patients treated with strong opioids, mostly methadone, for more than one year with a 
control group of chronic pain patients without opioid treatment [85]. Differences were found 
regarding the pituitary-gonad and pituitary-adrenal axis, including prolactin levels, indicating 
an opioid effect causing endocrine dysregulation. Typical symptoms were sedation, sweating, 
sexual dysfunction, gynecomastia, and low physical and emotional functions. An important 
finding was that function and quality of life was better in the control group of pain patients 
despite no differences in pain between the two groups. 
2.2.7 Interactions with other drugs 
Many medications can increase or decrease levels of methadone in the body. Weschules et al. 
found in a review of 200 articles that the evidence base associated with methadone drug 
interactions is underdeveloped in general, as most of the references found were case reports 
or case series from the MMT population, which may differ significantly from the cancer pain 
population [86]. Further, they highlighted that genetic polymorphism associated with the 
cytochrome‐P enzymes (CYP) may have a bearing on methadone‐related drug interactions 
[86]. 
Besides absorption, distribution and elimination, inhibitors and inducers of the CYP450 
enzyme system are of importance for the metabolism of methadone [66]. Administration of 
CYP450 inhibitors will reduce methadone’s metabolism, resulting in increased methadone 
levels. CYP450 inducers will have the opposite effect, which may even present as opioid 
abstinence symptoms. 
Examples of drugs that may increase methadone concentration include antibiotics 
(ciprofloxacin, erythromycin, trimethoprim), antidepressants (citalopram, fluoxetine, 
sertraline, paroxetine), antifungals (fluconazole, ketoconazole), benzodiazepines (midazolam, 




(celecoxib), neuroleptics (haloperidol), PPIs (omeprazole, esomeprazole, lansoprazole), 
TCAs (amitriptyline) and cannabinoids.  
Medications that may decrease methadone concentration comprise anticonvulsants 
(phenytoin, carbamazepine, phenobarbital), antiretroviral agents (nevirapine, rifampin) and St 
John’s Wort. [66, 87]. 
2.2.8 QTc prolongation 
Prolongation of the QTc interval can potentially result in fatal cardiac arrhythmia, Torsade de 
Pointes, though it is very rare. Several drugs often used in specialized palliative care have 
QTc prolonging effects, such as neuroleptics, antidepressants, octreotide and methadone [88]. 
There are conflicting reports concerning the correlation between the total daily methadone 
dose and prolongation of the QTc interval [89-95]. QTc prolongations of >500 ms are 
considered to be clinically significant [96, 97]. Patients with cancer often already have an 
increased risk of QTc prolongation due to cardiotoxic chemotherapy, use of QTc prolonging 
medications, radiotherapy to the chest and electrolyte disturbances [98]. Lovell et al. found 
that clinically significant QTc prolongation was present in 10% of cancer patients using oral 
methadone regardless of a low (mean 14.4 mg) or high (mean 86 mg) dose [97]. In 
methadone maintenance programs for opioid use disorder, ECG monitoring is typically 
initiated at the start of treatment and is then regularly performed in patients on high doses 
(>100 mg daily) or in the presence of other QT interval prolongation risk factors, including 
heart or liver disease, electrolyte abnormalities, concomitant treatment with CYP 3A4 
inhibitors, or other drugs with the potential to cause QT interval prolongation [99]. Overall, a 
dose higher than 30 mg of methadone daily seemed to add a risk of cardiac arrhythmia, but 
the benefits of methadone should greatly outweigh the risks of QTc prolongation, especially 
in patients receiving palliative care where doses of methadone often are 5-20 mg daily and 
ECG monitoring is usually not recommended [97, 100, 101].  
2.2.9 The non-oral route  
There are several reliable administration routes of methadone as the patient approaches the 
end of life and the oral route is no longer available. Conversion to intermittent IV or SC 
injections or continuous infusion via a syringe driver, are convenient in the palliative care 
setting. Unfortunately, SC methadone has been associated with subcutaneous erythema [102]. 
However, if the infusion site is rotated every one or two days or if the methadone is diluted, 
these reactions tend to be mild and manageable [103-106]. It has been reported in Germany 
that the levo-rotatory form of methadone (l/R-methadone) is not associated with local 
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toxicity, but the drug is not commercially available [107]. Methadone tablets or enemas that 
can be given rectally are often absorbed within 30 minutes and have a reliable oral to rectal 
dose ratio of 1:1. Oral solution can be used for sublingual or buccal administration 
effectively, but is limited by volume constraints (1-1.5 mL) [108].  
2.2.10 Ambulatory use 
There are concerns about methadone’s safety for outpatient use in palliative care. Overall, 
there are only a few reports on methadone use in outpatient clinics or home care. The studies 
are almost exclusively about opioid rotation to methadone, which in an ambulatory outpatient 
setting appears to be safe, with typical success rates of 70-80% and final methadone doses 
well below 100 mg daily [109-115]. Hawley et al. reported few adverse effects and only 2.3% 
hospital admissions when slow transition to methadone was practiced in their outpatient 
palliative cancer clinic [116]. In a prevalence study on 21,219 hospice patients in a home-care 
setting in Philadelphia, methadone accounted for 1.7% of all long-acting opioid prescriptions 
during the study period [117].  
2.2.11 Methadone in the elderly person 
Reports indicate that frail elderly patients should be initiated on much lower doses of 
methadone, perhaps as low as 0.5 mg daily in the oldest population, although starting doses 
of 2.5 mg b.i.d. are commonplace, which is still a low dose [82, 118, 119]. This could be due 
to age-related changes including increased fat composition and age-related decreases in 
activity of CYP enzymes responsible for methadone metabolism, both of which contribute to 
a prolonged half-life for methadone. Especially in elderly individuals, “starting low and going 
slow”, with a close follow-up, is central for the safe use of methadone [87].  
2.2.12 Low-dose methadone as an add-on to regular opioid therapy 
In patients with poor analgesic benefit after opioid dose escalation, the practice has long been 
to attempt a complete switch to methadone, with other opioids only being used for 
breakthrough pain [116]. In 2004, Mercadante et al. described a successful “opioid semi-
switching” regime aimed at breaking opioid escalation and regaining analgesia in 14 patients 
with cancer-related pain who had raised their opioid doses more than 100% in the last week, 
where fentanyl or methadone, in an initial equivalent dose of 20 % of the previous regime, 
was added [1].  
The next reports concerning adjuvant use of methadone as a low-dose add-on to an ongoing 




reporting 10 and 3 cases, respectively [120, 121]. The idea was that low-dose methadone can 
be safely and successfully used as a co-analgesic to another opioid if introduced cautiously, 
thereby benefitting from the NMDA-receptor antagonism, without having to do a complete 
switch to methadone in the usual manner and simultaneously minimizing the risks associated 
with methadone’s complex pharmacology.  This simpler regimen was thought to potentially 
be of particular use in palliative care services managing severe pain in the outpatient setting 
[120].  
There are a few rather small retrospective cohort studies [122, 123] that typically describe 
2.5-5 mg b.i.d. of oral methadone added safely to a regular opioid for analgesia in complex 
cancer-related pain. Methadone doses are stabilized at 10-15 mg daily within a week, and 
improved pain control is reported in 49-75% of the cases. In a recent study from 2019, Chary 
described the use of an ultralow add-on regime, starting with 1 mg daily and increasing the 
daily dose by 1 mg once a week up to a maximum of 20 mg methadone daily, with a slow 
onset of analgesia [124]. Furthermore, Courtemanche et al. observed a plateau in response to 
an increasing methadone dose, suggesting that patients who responded to a low dose of 
methadone might not experience a further reduction in pain intensity if the methadone dose 
was increased, compared with if maintained at the same level [123].  
At our own institution, the first clinical attempts to use methadone as an add-on drug were 
carried out about 15 years ago. The add-on low-dose methadone regimen is promising and 
could have the potential to change future medical practice, thereby improving quality-of-life 
for numerous patients. 
2.2.13 Knowledge gap 
The studies conducted on low-dose add-on methadone have shown promising results. The 
two larger studies of Wallace and Courtemanche are both retrospective observational studies 
that reported analgesic effect in some patients who received the treatment [122, 123]. The 
patients often had several months left to live. Courtemanche made an attempt to seek 
characteristics for those patients who seemed to benefit from  low-dose add-on methadone. 
With multivariate analysis it was shown that subjects with a higher pain score intensity at 
initiation were more likely to respond to adjuvant methadone with analgesia during the first 
week, the only association found. Patients who had already responded to a low dose of 
methadone did not appear to benefit from a further dose escalation.  
In all, this leads to questions as to whether the use of low-dose add-on methadone in patients 
with cancer-related pain can be successfully used even during the last days of life. Due to the 
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methodological difficulties of studying pain in imminently dying patients, this is an under-
researched area. Would imminently dying patients benefit from add-on methadone and are 
there patients who benefit from it better than others? Which doses are adequate in dying 
patients? If low-dose add-on methadone is already an established treatment: how common is 
it, who prescribes it and to whom and how? What do dosages, opioid combinations and 
adverse effects look like? Can low-dose add-on methadone be safely used in home care? If 
methadone is best known in the context of opioid withdrawal, can attitudes toward 
methadone affect the conditions for using it for pain in palliative care? Thus, effects, adverse 
effects, prevalence of use, indications, practical use, and attitudes to methadone need to be 
further explored.  
In addition, if low-dose add-on methadone is a good treatment, may it then be continued 
parenterally without risk of increased adverse effects, should the oral route become 
unavailable during the last days of life? 
2.3 THE SWEDISH REGISTER OF PALLIATIVE CARE (SRPC) 
The SRPC is a national quality register that contributes to the research and development of 
palliative care in Sweden [125]. The registration is made by the responsible staff through an 
online end-of-life questionnaire (ELQ) after the death of a person. The ELQ provides 
information concerning, for example, demographics, diagnoses, prevalence, and changes of 
either severe pain, breakthrough pain, anxiety, dyspnea, nausea, delirium, or death rattles 
during the last week of life. The questions reflect quality of care delivered during the last 
week of life, irrespective of age, diagnosis, or care setting. In 2016, when Study II was 
initiated, 10.8% of the 91,029 persons who died in Sweden were enrolled in specialized 
palliative care and registered in the SRPC, which corresponds to 90-100% of all patients that 
died in specialized palliative care [126]. In total, 64% of all deaths during 2016 were reported 
to the SRPC [126]. 
Since, anecdotally, low-dose methadone as an add-on is practiced by an increasing number of 
physicians nationally, particularly in palliative care, there is a need for further exploration of 
this topic. The SRPC network is well suited to provide the basis for investigations of 
prevalence and indications for low-dose methadone add-on therapy in cancer-related pain. 
2.4 QUALITATIVE RESEARCH 
Well-validated instruments are preferably used in quantitative research, e.g., in quality of life 
studies. A validated instrument has high validity (it measures well what it is intended to 




results) and sensitivity (the ability to find differences between groups). A disadvantage of 
such instruments with predefined questions best suited for a given context, is the risk of 
missing important aspects not asked about. For example, the same questions can be 
perceived, evaluated, and answered completely differently by a cancer patient when early on 
in the course of the disease, or when being close to the end of life.   
Qualitative research methods can explore, uncover, describe, and understand what lies behind 
phenomena about which little is known and may often be used in the early phase of a study to 
explore an area on first entry into the field to obtain clarity or to clarify hypotheses [127]. 
Qualitative research that explores a partially unknown phenomenon is often a basis for 
planning a quantitative study. Qualitative research delineates different aspects of a 
phenomenon, whereas subsequent quantitative research quantifies the aspects. 
However, qualitative research also has other areas of use. For instance, the qualitative method 
can be used to deepen the knowledge about outliers. As mentioned above, a predefined 
questionnaire risks missing unexplored areas. For example, the important aspects are known 
for a certain phenomenon which is then examined quantitatively with a questionnaire. If the 
vast majority respond positively to a central question and perhaps just five percent answer 
negatively, then interviews with these outliers can provide important knowledge about why 
the question did not suit them.   
Qualitative methods can be very useful to produce new ideas and there is space within the 
research structure to explore new ideas as they arise [127]. Used along with other types of 
research it also gives additional perspectives on the problem, i.e., it can produce results that 
directly represent how people think and feel.  
2.4.1 Qualitative interviews  
In healthcare research, both semi-structured and in-depth interviews are common methods for 
data collection. In semi-structured interviews, a prepared interview guide with open-ended 
questions is applied. Follow-up questions are then used to further explore the phenomenon of 
interest [128-130]. To explore an issue in-depth, but perhaps not cover as many aspects, in-
depth interviews can be used. The questions in such an interview should be open-ended, often 
neutral, sensitive and not difficult to understand [129]. The most important aspect during the 
interview is to try to capture as many details as possible and make sure to find and investigate 
new and unexplored information [129]. Instead of taking notes, audio recording of the 
interview can be a good way for the interviewer to both capture details and be able to be more 
 
22 
engaged during the interview. The recording is then transcribed verbatim or in a near-
verbatim mode [131]. 
2.4.2 Sampling 
Sampling in qualitative research is not based on the same scientific assumptions as in 
quantitative research. Quantitative research often uses total cohorts or large randomized 
samples and calculates probabilities. In qualitative research, where the goal is often to capture 
as many nuances of a phenomenon as possible, purposeful sampling is a common technique 
often used to identify and select information-rich cases [129]. 
There are various purposeful sampling techniques such as single significant cases sampling 
(to reach a more thorough understanding of the person), comparison focused sampling 
(people are selected to be compared and to find differences among them) and group 
characteristic sampling (cases are selected to create a group as rich as possible in 
information). One variant of group characteristic sampling is the so-called maximum 
variation sampling, where people are selected in order to find as varied characteristics as 
possible, but also common patterns. 
In qualitative research, the sample sizes are often smaller than in quantitative research, 
typically 10-25 cases and the sample size is often not predetermined. Instead, an important 
concept is saturation, originally a concept in grounded theory [132]. Saturation roughly 
means that further data collection from additional cases does not provide much more new 
essential information and that the collection therefore can be completed [133]. 
2.4.3 Analyzing qualitative data 
There are different approaches to analyzing qualitative data. Qualitative content analysis, 
which was used in this thesis, is a method used to explore the content and meaning of a text 
by systematically searching for and classifying data and ultimately shaping overarching 
themes based on the common data [128]. It is a step-by-step analysis that usually starts with 
reading the transcribed text repeatedly to really immerse oneself in it. Then meaning units are 
identified, i.e., short text segments representative of different aspects in relation to the 
research question. The meaning units are given short new names, codes, which are then 
compared and grouped into categories, i.e., groups with codes that have something in 
common. Finally, themes are searched for, i.e., threads through the data with a common 
underlying meaning [128, 134, 135]. In an inductive analysis, the data is interpreted bottom-
up to create new concepts and categories that can be used to classify phenomena that have not 




abductive, approach means that data is analyzed based on an already existing theoretical 
framework, top-down [129, 135]. Additional important terms are latent and manifest. In 
latent analysis, the underlying meaning of the text is searched for and interpreted, while 
manifest analysis is more descriptive in its nature and focuses more on what the informants 
really said and stays close to the text [134]. 
To conclude, the choice of qualitative method is based on the research question and the type 
of phenomenon that is analyzed. The researcher, therefore, has to take into account different 
considerations such as the depth of the analysis, i.e., a descriptive analysis (mainly manifest 
data) or an interpretative analysis (latent data) and whether theories already exist that are 
useful as a theoretical framework for the analysis. If so, then a hermeneutic approach is 
possible for example, or, if the focus is on the process rather than the content, then Grounded 
theory could be an option. 
2.4.4 Trustworthiness 
Qualitative research is often based on texts originating in interviews or observations. A text 
always involves multiple meanings and there is always some degree of interpretation when 
approaching a text [134]. This is essential when discussing the trustworthiness of findings in 
qualitative content analysis [134].  
Graneheim et al. described how research studies must be evaluated in relation to the 
procedures used to generate the findings to be as trustworthy as possible [134, 136]. The 
concepts of credibility, dependability and transferability were used to describe various 
aspects of trustworthiness in qualitative research [134].  
Credibility is about how well the data and analysis really address what was intended to be 
investigated [134]. It starts with the structure of the study, for example how and in what 
context one intends to select participants and collect the data. Informants with different 
experiences increase the opportunity to shed light on different aspects. Then it is important to 
choose the most appropriate meaning units and categorize and create themes that cover the 
data. Credibility is also the demonstration of how to assess similarities and differences 
between categories, for example by presenting representative quotations from the transcribed 
text [134]. Another way is to seek agreement on how data is sorted among co-researchers, 
experts and participants [134].  
Dependability is how much both the data collection and the researcher's decisions change 
during the analysis process [134]. Interviews and observations are developing processes 
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where the researcher continuously gains new insights about the phenomenon being studied 
and which can then influence follow-up questions or limit the focus of observation. 
Transferability is the extent to which the results can be transferred to other settings or 
groups [134]. Here, researchers can only make suggestions, but it is the reader's decision 
whether the results can be transferred to another context. This is facilitated by providing a 
clear description of the participants' context, selection and characteristics, data collection and 
analysis process [134]. Also, a complete presentation of the results along with appropriate 
quotes improves the transferability. 
In summary: whereas validity is a strength (informants narrate a picture that is valid to them) 
in qualitative research, results are not easily generalizable due to the methodological 
assumptions and, especially, due to the need of using purposeful sampling strategies.  
However, data may be transferable to similar contexts and in some cases also beyond the 
original context [127]. One example is the concept of SOC (sense of coherence) that was 
coined by Aaron Antonovsky. His original study was on females who survived Nazi camps, 
but since then, the concept of SOC has been applied to various contexts within health care. 
 In this thesis, qualitative research methods were required to enable an exploration of the 
attitudes and opinions of physicians, patients and their families regarding methadone and its 






The overall goal of this thesis was to study the use of low-dose methadone in addition to 
other ongoing opioid treatments for complex cancer-related pain in specialized palliative care 
in Sweden.  
The specific objectives of Studies I-IV were: 
I. To investigate whether a low-dose add-on of methadone to another ongoing opioid 
therapy could contribute to pain relief in dying patients with complex cancer pain, as 
well as examining the possible adverse effects in the form of sedation, delirium and/or 
respiratory depression. 
II. To investigate the use of methadone in specialized palliative care in Sweden and 
specifically explore the frequency of use, indications, doses, opioid combinations and 
adverse effects when using low dose methadone in combination with other opioids at 
the end-of-life. 
III. With the aid of semi-structured interviews, to broaden and deepen the understanding 
of attitudes about, potential significance of and practical aspects regarding the use of 
methadone for pain in specialized palliative care. Further, to identify new areas of 
future research.  
IV. To prospectively study analgesic and adverse effects when prescribing subcutaneous 
infusion via an ambulatory infusion pump to imminently dying patients in specialized 




4 MATERIALS AND METHODS 
4.1 OVERVIEW 
An overview of the materials and methods used in the studies in this thesis is provided in 
Table 1. 
Table 1. Overview of materials and methods used in Studies I - IV 
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4.2 STUDY DESIGN 
This thesis includes four studies, all performed within specialized palliative care. Study I is a 
retrospective observational study that assesses pain, opioid doses, and adverse effects. Study 
II is also a retrospective observational study examining the prevalence of, indications for, 
doses of and reported effects of methadone treatment for pain. Study III is a semi-structured 
interview study to explore attitudes to and practical aspects of methadone for pain. Study IV 
is a prospective observational study to investigate symptoms, opioid doses including 
methadone doses and adverse effects in pain relief delivered via continuous subcutaneous 
infusion. 
4.3 DATA SOURCES 
4.3.1 Medical records - TakeCare  
TakeCare is a single-sign-on medical system for medical records [137]. It connects staff to all 
other systems and handles electronic medical records, with one shared record per patient. 
TakeCare covers 90% of the care providers in Stockholm County [137].  
4.3.2 The Swedish Register of Palliative Care 
The Swedish Register of Palliative Care (SRPC) was established in 2005 and is based on a 
validated on-line end-of-life questionnaire (ELQ) with 30 questions that is completed soon 
after the death of a patient by the nurse or physician in charge. The questions reflect quality 
of care delivered during the last week of life. The SRPC is a national quality register and in 
2019, it covered 60.2% of all deaths and close to all of the deaths in specialized palliative 
care in Sweden [125]. An important purpose of the registry is to contribute to research and 
development of palliative care in Sweden.  
4.4 STUDY POPULATION 
4.4.1 Study I 
For the purpose of Study I, all deceased patients at the specialized palliative care unit at 
Stockholm Sjukhem Foundation who, during the years 2006-2013, received treatment with 
methadone for pain relief were identified within the TakeCare medical record system. The 
unit is a tertiary palliative care center for patients over 18 years of age and most patients 
suffer from advanced cancer. All identified patients who were prescribed a peroral add-on of 
low-dose methadone to another ongoing opioid therapy for cancer-related pain, constituted 




4.4.2 Study II 
For the purpose of Study II, all known specialized palliative in-care and home care units in 
Sweden using the SRPC were invited to participate by having an additional questionnaire 
added to their regular ELQ. This additional on-line survey covered the use of methadone in 
individual patients and was completed by the responsible registered nurse or physician. The 
participating units contributed to data collection for twelve months, with starts from January 
to June 2017. All patients registered by the participating units during the study period 
constituted the study population.  
4.4.3 Study III  
For the purpose of the qualitative Study III, we intended to capture the width of the 
information the participating informants could contribute to. Thus, the participants were 
selected with purposeful maximum variation sampling among physicians in active clinical 
service in specialized palliative and pain care in Sweden. We aimed for as much variation as 
possible in terms of age, gender, geographical place of work, level of education and 
experience. The prospective informants were contacted via email. Everyone who was 
contacted chose to participate in the study. The interviews were conducted at each informant's 
workplace from November 2017 to February 2018. The number of informants in the study 
was largely determined by when “saturation” began to be achieved, i.e., when the data 
obtained in each additional interview did not contribute to additional information of value and 
when increasingly clear patterns in the collected data could be seen. Saturation began to 
appear around 15 interviews and was clear at about 20 interviews. The data collection was 
continued to a total of 30 interviewed physicians in order to be able to assess with greater 
certainty that further aspects did not appear. Informed consent was obtained from the 
participants. 
4.4.4 Study IV 
For the purpose of Study IV, participation was asked of imminently dying patients who were 
neither sedated nor unconscious and who were prescribed continuous subcutaneous infusion 
(CSCI) for symptom control while admitted to the specialized palliative care in-patient unit at 
Stockholms Sjukhem. Informed consent was obtained from each patient and, thereafter, the 
patients were monitored for symptoms and medication daily until the end of life. Since this 
was a descriptive study no sample size was calculated. 
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4.5 DATA COLLECTION 
4.5.1 Study I 
In Study I, the data collection was exclusively performed using a manual review of medical 
records from deceased patients, covering the time from three days before methadone was 
initiated up to and including seven days after initiation. Background data were obtained from 
the medical records regarding, for example, demography and disease, the use of opioids and 
other medications.  
Furthermore, two independent physicians read each patient record individually and, using a 
structured template developed for the study, made assessments from the records regarding 
pain type and intensity (no / mild, moderate or severe) that the patient appeared to have 
experienced during each separate day. In order to estimate the consistency of the pairwise 
assessments, the two physicians then compared their assessments. In 69% of the assessments, 
they had made exactly the same grading of pain intensity, a similar assessment (one pain 
level difference or less on a single day) in 25% and in only 6%, did the assessed pain levels 
differ by two steps. The deviating assessments were discussed together and after this the 
assessors agreed on all the pain assessments, which are presented in the study. Similarly, the 
presence or absence of confusion/delirium (based on DSM-IV criteria), sedation, and 
respiratory depression were assessed. 
4.5.2 Study II  
In Study II, data were used from both SRPC's regular ELQ and from the supplementary 
survey, which was mandatory to complete for participating units over a twelve-month period. 
The regular ELQ, which in specialized palliative care in Sweden is completed for 90-100% of 
individual patients and covers the patient's last week of life, provides data concerning 
demographics, diagnosis, prevalence and changes in pain and other symptoms, i.e., nausea, 
dyspnea, anxiety or death rattles. It also reports whether validated assessment instruments for 
pain and other symptoms were used. 
The supplementary survey questionnaire was designed to specifically examine the methadone 
use of each individual patient initiated on the drug during their time in specialized palliative 
care. The questions were developed through discussion by an expert group consisting of 
physicians with a broad expertise in pain treatment and pain research that included a 
professor of palliative medicine, an author of books on pain, a specialist in palliative 




questions were tested in a pilot study and revised three times before the study was launched. 
The questionnaire included questions about the indications and doses of methadone and other 
opioids. The effects on pain and possible adverse effects were based on patient-reported 
outcome measures and were transferred by the reporting staff to a four-point Likert scale 
where the effect of the methadone initiation was assessed on a scale from very good to no 
effect at all. Adverse effects were rated as present or not. In addition, the questionnaire 
included questions concerning the medical experience of the prescribing physician and 
whether any other specialist physician had been consulted regarding the use of methadone. 
(See Appendix I for the supplementary survey questionnaire of Study II) 
4.5.3 Study III 
In Study III, data was collected in the form of semi-structured interviews that were audio-
recorded and then transcribed verbatim. Initially, the interview guide was pilot tested on two 
informants. The questions concerned attitudes to methadone and their prescription of 
methadone for pain in specialized palliative care. Question examples include: “Describe any 
occurring prejudices about methadone that you have encountered [in colleagues, staff, 
patients or their next of kin]”, “Tell me about your experience of treating pain over the 
years”, and, for physicians positive to methadone use: “Describe a patient who you would 
expect to benefit from the use of methadone for analgesia”. The open-ended character of the 
questions allowed, when needed, for follow-up questions. Also, further questions were added, 
and new emerging areas of interest were explored. The interviews lasted for 30-55 minutes. 
(See Appendix II for the semi-structured interview-guide of Study III) 
4.5.4 Study IV 
The patients in Study IV were at the absolute end of life with a gradual deterioration in the 
general condition to be expected. Therefore, it was a basic condition that the daily 
assessments of the patients' symptoms could be performed regardless of whether the patients 
could participate or not. The proxy version of the Integrated Palliative Care Outcome Scale 
(IPOS) was used to estimate patients’ symptoms and relatives' concerns. The Richmond 
Agitation and Sedation Scale (RASS) was used for assessing level of patient alertness, the 
Eastern Cooperative Oncology Group (ECOG / WHO) for performance status and the 
Confusion Assessment Method (CAM) instrument was used for assessing delirium. The 
patient's responsible registered nurse for the day completed the instruments after caring for 
the patient during his or her work shift. (See Appendix III for the start protocol of Study IV) 
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4.6 MEASUREMENTS OF SYMPTOMS AND ADVERSE EFFECTS 
NRS/VAS, ESAS or IPOS constituted the basis for the evaluations of pain intensity and 
adverse effects in Studies I, II and IV. In Study I, a supplementary study-specific template 
was used for the assessment of the patients. Additionally, in Study IV, RASS, ECOG/WHO 
and CAM were used for assessments of adverse effects and other symptoms. 
In Study II, pain intensity and adverse effect-reports were, in 84% of patients, based on 
NRS/VAS, ESAS or IPOS evaluations.  
For missing data in Studies I and IV, last observation carried forward was practiced.  
4.6.1  Study-specific template  
In Study I, the information concerning the patients' intensity of pain and the occurrence of 
delirium and sedation were collected retrospectively from the medical records. Due to sparse 
registration, VAS/NRS registrations were not a reliable source of information. Therefore, in 
addition, the assessing researchers used a template as follows: 
With few or no descriptions of oral complaints (awake patients) or pain behavior (anxiety, 
grimaces, etc. in unconscious patients) the pain was classified in the records as none or mild. 
The need for single extra doses of analgesics, a few complaints of pain or a more regular pain 
behavior (unconscious patients), was judged as moderate pain. Descriptions of significant 
pain or use of regular rescue doses was considered as presence of severe pain. Whether 
delirium was present or not was classified based on the DSM IV criteria. In the same way, 
sedation was judged as either no sedation or any degree of sedation. The assessments of 
respiratory depression related to respiratory rate, and impaired respiration was considered to 
exist if there were notes from physicians or registered nurses about clinical signs of 
respiratory depression (e.g. "breathing slowly" or "only eight breaths per minute"). 
In order to strengthen the assessments, the templates were used by two independent reviewers 
(physicians) who performed their assessments separately and then compared their findings. In 
cases of initial disagreement, the patient was discussed, and a consensus was found. 
4.6.2 Visual Analogue Scale (VAS) and Numeric Rating Scale (NRS) 
The Visual Analogue Scale (VAS) and the Numerical Rating Scale (NRS) are 11-point 
graded (0 = no symptom, 10 = worst possible) scales for the self-reporting of pain or other 
symptoms in cognitively intact adults. Of these, NRS is recommended on the basis of higher 
compliance rates, better responsiveness, and ease of use relative to VAS, especially in 




4.6.3 Edmonton Symptom Assessment Scale (ESAS) 
ESAS is a clinical tool to document the symptom burden in patients with advanced cancer 
admitted to a palliative care unit covering pain, fatigue, nausea, depression, anxiety, 
drowsiness, shortness of breath, appetite, feeling or well-being and an optional category, 
often used for sleep or constipation [138]. Over the years, ESAS has evolved. Initially, each 
symptom was assessed in a VAS (visual analogue scale) format, but this has today often been 
replaced by the 11-point NRS (numeric rating scale) format. A one step change is considered 
a minimal clinically important difference [139]. 
4.6.4 Integrated Palliative Care Outcome Scale (IPOS)  
IPOS consists of 10 questions regarding symptoms, anxiety, anxiety in relatives, feelings of 
being at peace, need for information and practical problems [140]. There is a patient-reported 
version and a staff version (proxy rating). The questions are answered on five-point Likert 
scales. The staff version enables assessment even when the patient is unable to self-report and 
was used consistently throughout Study IV. IPOS was used to prospectively assess patients’ 
symptoms and relatives' concerns, as well as the variables for pain and anxiety on a daily 
basis. The assessments referred primarily to the patient's situation during the past 24 hours. 
IPOS has been validated in Swedish and is widely used in specialized palliative care in 
Sweden [141].  
4.6.5 Richmond agitation and sedation scale (RASS) 
The RASS is a 10-point scale assessing level of consciousness and agitation, ranging from +4 
(combative) to -4 (unarousable). Zero means alert and calm and corresponds to the neutral 
level [142]. RASS was originally developed for intensive care but has been validated for 
patients being treated with palliative sedation and is reliable for patients both with and 
without sedative drugs. RASS has no subscales, is fast, clear and easy to use. It has a high 
inter-rater reliability and high validity with other scales [142]. It is available in Swedish 
[143]. 
4.6.6 ECOG/WHO 
Performance status according to ECOG/WHO is a simple scale without subscales developed 
for cancer patients that indicates an assessment by a physician or nurse regarding the patient's 
general condition. The scale comprises six steps from 0 (manages all activity without 
limitation) to 5 (dead) [144].  
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4.6.7 Confusion Assessment Method (CAM)  
CAM is an instrument consisting of four questions to assess whether delirium is present or 
not in a patient, based on DSM criteria [145]. It is short and fast, validated, and frequently 
used in research. It has been translated into Swedish. CAM is not considered appropriate for 
grading the severity of delirium [146]. 
4.7 DATA ANALYSES 
4.7.1 Statistical methods 
The statistical analysis used in the studies are listed in Table 1. Overall, standard descriptive 
statistics were used for patient characteristics, including presentation of medians with 
interquartile ranges and means with standard deviation.  
Comparisons 
In Studies I, II and IV, t-tests were used for the calculations of statistical significance between 
groups with normally distributed data. Otherwise, non-parametric tests were used, Chi-square 
for comparison of proportions or Fisher's exact test for small groups. The Mann-Whitney U 
test was used for comparing independent groups and the Wilcoxon signed-rank test for 
dependent groups, respectively. In all calculations a p-value < 0.05 was considered 
statistically significant. 
4.7.2 Qualitative content analysis 
A qualitative conventional content analysis in accordance with the description of Hsieh et al. 
was performed [128]. This method is often applicable when there is only a limited amount of 
literature or theory about a phenomenon. The analysis followed the following steps: 
1. In order to delve deeper into and become better acquainted with the material, the texts 
were read through several times. 
2. The text was then read carefully word for word to identify meaning units, i.e., words 
or text segments, important patterns and subjects of potential interest with respect to 
the research question. The short segments were given short names, as preliminary 
codes. 
3. Based on meaningful differences and similarities, the preliminary codes were sorted 
into groups, ie., preliminary categories. As far as possible, the informants' verbatim 
formulations were used. 
4. The preliminary categories were compared and then carefully examined to find the 




5. Finally, the preliminary categories were combined and four final categories or themes, 
were created. These four final categories represented different aspects of the 
underlying meanings of what the informants had presented. 
6. The final categories were discussed by the researchers and revised as needed to 
achieve agreement. 
The free software OpenCode 4.0 from Umeå University was used to manage the data [147]. 
4.8 ETHICAL APPROVAL 
Ethical approval for all four of the studies was obtained from the Regional Ethical Review 
Board in Stockholm with the following diary numbers: 
• Study I: 2013/1814-31/2, 2014/835-32 
• Study II: 2015/1486-32 
• Study III: 2017/2302-32 





5.1 STUDY I 
Of the 4233 patients who were cared for during the study period, 165 were prescribed 
methadone in any form for pain and, in 80 of these, as peroral add-on of low-dose methadone 
to another ongoing opioid therapy for cancer-related pain. These 80 patients made up the 
study population. A majority were women (64%), the mean age was 68 years and the most 
common cancer diagnoses were of urogenital, gastrointestinal, pulmonary or breast origin. 
One patient had local disease only, the rest metastatic disease. Half of the patients had a 
documented pain mechanism, in 80% it was neuropathic or mixed neuropathic and 
nociceptive.  
At the time of methadone initiation, regular opioids used were oxycodone (38%), morphine 
(36%), fentanyl (19%) and hydromorphone (8%). The median total MEDD of opioids (except 
for methadone), i.e., regular and rescue-doses, was 290 mg (IQR 505).  
The median dose of methadone was 10 mg (IQR 5) on the first day and still 10 mg (IQR 10) 
one week later. However, the methadone dose was increased in 67% of the patients during 
the week. During the same period, the total median MEDD of other opioids decreased to 250 
mg (IQR 358). 
5.1.1 Change in pain 
As many as 80% of the patients were assessed to have reached better pain control during the 
period from when methadone was initiated until one week later (p < 0.001). The proportions 
of patients who were assessed to have no or mild, moderate, and severe pain changed from 
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5.1.2 Adverse effects 
As expected in end-of-life care, both delirium and sedation increased during the last weeks of 
the patients’ lives, which constituted the study period. The increase was significantly more 
pronounced in patients with a survival time of less than 14 days, i.e., 80% of the patients with 
shorter survival were assessed as sedated or delirious. There were only severe symptoms in 
17% and 21% of the patients with shorter survival, respectively, and there was no report of 
respiratory depression. Due to methodological reasons, it could not be distinguished as to 
which proportions methadone and the dying process contributed to sedation and delirium. 
5.2 STUDY II 
In total, 133 specialized palliative in-care and home care units in Sweden were invited. With 
a good geographical representation from throughout the country (Figure 2), 60 (45%) units 
chose to participate. During the study period, a total of 10,058 ELQs were registered 
nationally. Of these, 4780 ELQs were registered by the participating units, corresponding to 
48% of all deaths of patients admitted to specialized palliative care during the study period. 
Methadone was initiated in 410 (8.6%) patients. These patients constituted the study 
population.  
FIGURE 2. GEOGRAPHICAL REPRESENTATION OF SPECIALIZED PALLIATIVE 
CARE UNITS PARTICIPATING IN STUDY II 
Each dot represents one of the 60 participating specialized palliative care units in Sweden 





The mean age of the patients who were initiated on methadone was 68 years and 41% were 
women. In those who did not receive methadone, the mean age was 74 years and 55% were 
women. In one third of the patients methadone was initiated in home care. Eighty-seven and 
82 percent had a cancer diagnosis in the methadone and non-methadone groups, respectively.  
5.2.1 Indications 
In the 410 patients who had been initiated on methadone, 96% were prescribed low-dose 
methadone as add-on to another ongoing opioid. The most common indication (74%) was 
unsatisfactory pain control with the current analgesic therapy. The underlying pain 
mechanism had been assessed in almost all patients (96%). Of these, 70% had mixed 
neuropathic and nociceptive pain, 16% neuropathic pain, 11% nociceptive, and uncertain 
mechanism in 3%. Methadone was used as the primary opioid for neuropathic pain in 17% of 
the patients.  
Validated instruments for assessing the level of pain were used in 84% of the patients and 
instruments for assessment of other symptoms in 50%. Forty-six percent had a reported pain 
level exceeding 6 out of 10 on VAS/NRS, ESAS (or IPOS) at least once during their care 
period. In 94%, methadone was reported to have added a good or very good analgesic effect. 
5.2.2 Methadone and other opioids  
Methadone was used for a median of 21 days (mean 48). In 86% of patients the reason for 
discontinuation of methadone was death, but in 10% it was due to an inability to swallow 
tablets at the end of life.  
The most common regular ongoing opioid combined with methadone was fentanyl, used by 
half of the patients. One third (32%) used oxycodone, 11% morphine, 6% hydromorphone, 
1% ketobemidone and 0.3% buprenorphine. For doses of regular opioids and methadone, see 
Table 2.  
TABLE 2. OPIOID DOSES IN STUDY II 
 
Daily opioid doses (mg) at initiation 
of methadone 
Daily opioid doses (mg) 
during the last 24 hours 
Median MEDD (IQR) 184 (IQR 155) 199* (IQR 150) 
Median methadone dose 5 (IQR 5) 10*** (IQR 10) 
* p < 0.05; ***p < 0.001   
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Methadone doses were increased in 70% of the patients during the study period. At initiation, 
peroral methadone twice daily was the most common prescription, but during the last 24 
hours intermittent SC injections two times per day dominated. Only 2% of the patients were 
prescribed continuous SC or IV infusion of methadone during the last 24 hours.  
5.2.3 Adverse effects 
In the vast majority of patients (80%) there were no reported adverse effects. In 8.5% 
sedation and in 7.3% delirium was reported. During the last 24 hours, opioid doses were 
higher in delirious than non-delirious patients (median MEDD 242 mg vs 195 mg) while the 
opposite was true for methadone doses (10 mg vs 15 mg). There were no serious cases of 
respiratory depression.   
5.3 STUDY III 
In Study III a qualitative method was used. With the aid of semi-structured interviews, 
attitudes, significance, and practical aspects of methadone use in specialized palliative care 
were explored. Of the 30 physicians interviewed, 22 were women, the mean age was 53 years 
and their experience in palliative or pain medicine ranged from 8 months to 40 years.  
Main categories and subcategories  in Study III 
Attitudes 
Physicians and staff 
Attitudes among patients and relatives 
Indications 
Mechanism-based prescription 
End-of-life situations with short life expectancy 
Practical use 
Low-dose add-on strategy 
Effects and adverse effects 
Initiation, settings 
The dying patient 
Refractory pain situations 
 
5.3.1 Attitudes 
According to the descriptions made by the informants, association with substance use 
disorder occurred, especially among patients and relatives but, in general, attitudes to 




Attitudes to methadone as an analgesic varied. Among physicians and other staff, some were 
skeptical that methadone had any unique properties compared with other opioids, while 
others were almost over-optimistic about the possibilities of methadone. 
Among some palliative care physicians, methadone was described as almost a magic bullet, 
while others emphasized the risk of overconfidence in an individual drug and the risk of 
neglecting other therapeutic options. The latter perception occurred among pain physicians 
who, although partially recognizing a unique role of methadone, had not seen long lasting 
effects. The differing views on the benefits of methadone were explained by the palliative 
physicians being due to the fact that they saw dying patients more often and that they 
therefore usually worked with shorter time perspectives.  
[Palliative specialist:] “But, I have seen how they [the pain specialists] have struggled with 
the same patients that we have later achieved analgesia for. No, we usually do not involve 
them, only when intrathecal catheters are required. Otherwise not, since we have a better 
understanding of these things [=in this special context]. I know—I am not being very humble 
[in this matter].” 
[Pain specialist:] “Sometimes you see a remarkably good short-term effect of a low dose 
[methadone]as add-on. But I don’t think the effect will last.. . .//. . .In the selected group of 
patients that I meet, it is extremely rare that you see any differences [in pain] when you 
discontinue methadone treatment [after a longer period of treatment], it makes no 
difference.” 
5.3.2 Indications 
Methadone was highlighted as having the greatest significance primarily in two situations: 
First, in the treatment of long-term severe cancer-related pain in palliative care, especially in 
situations with a rapid increase in opioid doses with only a limited effect on the pain control. 
Second, in situations with complex pain at the absolute end of life where rapid effect against 
mixed nociceptive and neuropathic pain was required. In both cases, low-dose add-on to 
another opioid was advantageously used as the routines for insertion and dose increases were 
considered simple. 
[Palliative specialist:] “First you just raise the basic dose of opioids, but when you start 
coming up in dose and it does not help then I would immediately say to try methadone, just 
because it influences neuropathic pain . . .//. . . It is fantastic, I could sell it. 
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Combining a low dose of methadone with another opioid for mixed pain was sometimes 
perceived as having an unexpectedly rapid and good effect, similar to the effect seen with 
ketamine, but the advantage of tablet treatment with methadone was emphasized as 
important. 
“Some patients improve. They get a better pain effect than you would expect from five 
milligrams, if you see what I mean.” 
Others that could benefit from methadone, according to the informants, were elderly patients 
or patients with renal failure.  
About half of the patients who received combination therapy with methadone were perceived 
to reach improved pain control. Their pain preceding the treatment was typically described in 
terms of "wind-up", "central sensitization", "exhausted pain system", "receptor fatigue" and 
"opioid tolerance". Pain originating from skeletal metastases or pathological fractures as well 
as pain from the spine or pelvis was described to benefit extra well. Cancer of the prostate, 
breast, kidney, pancreas, and sarcoma were mentioned as typical examples of diagnoses 
where analgesic effect could be seen. 
5.3.3 Practical use 
A much-discussed aspect of prescribing methadone was the risk of delayed respiratory 
depression and this was given as a recurring reason for the use of low-dose add-on 
methadone. The purpose of the methadone use was to achieve NMDA-receptor inhibition. 
The dosing strategy appeared very similar at many palliative care units. Usually 2.5 mg of 
methadone two or three times daily was added to an ongoing opioid treatment. After about 2-
7 days, the methadone dose was increased, if needed. Often, dose increase stopped at 5 mg 
twice daily and sometimes at 10 mg twice daily. Higher dosing was seldom used since it was 
not considered to provide an additional analgesic effect.  
The analgesic effect often appeared within a few hours or a day. With improved pain control, 
the risk of adverse effects, especially sedation, increased instead. Experienced physicians 
often perceived occurring sedation as an effect of the already ongoing high-dose opioid 
treatment and recommended therefore, at the first signs of analgesic effect of the methadone 
introduced, the dose of regular opioid to be reduced by 25-30%. 
“If you have a pain that is almost not morphine sensitive at all, you can increase to very high 




stem]. If you then add something [addressing another pain mechanism] that makes you pain 
free, you still have the high [opioid] dose and the whole problem [with adverse effects] 
emerges.” 
If the regular opioid treatment was not reduced, effects and adverse effects were seen to 
appear in a certain order, often 2-4 days after the initiation of methadone. First there was 
reduced pain, then cognitive impairment, then sedation and finally respiratory depression. 
When the patient was imminently dying and had difficulty swallowing, the tablets were 
usually discontinued. Intermittent methadone injections were then used and sometimes 
methadone was added to a CSCI. However, sometimes methadone was completely 
discontinued. 
Add-on methadone was also reported to be safely initiated in the home environment if good 
and daily contact, by visits or telephone, could be maintained with the patient or their 
relatives for 3-5 days after the methadone initiation. 
5.3.4 Refractory pain situations 
According to the informants, methadone, although a valuable tool in the treatment arsenal for 
individual patients, was not the solution to all complex pain situations with often several 
different pain mechanisms involved. Death anxiety, existential suffering and social pain were 
highlighted as major challenges and these conditions were described as difficult to master 
with drugs alone. 
“Severe pain is a matter of so many different components, not only physical pain. The 
physical pain itself is often the simplest part, whereas the existential and the psychosocial 
components are the most difficult.” 
5.4 STUDY IV 
The last study in this thesis was a prospective observational study. Of 321 potentially eligible 
patients, 93 were eventually included. Most of the dropouts, 88%, were due to a certain 
amount of gatekeeping: they were considered too fragile, in a physical or psychological 
sense, by the staff. Twelve percent of the patients abstained from participation. The 
participants were followed until death, a median of four days. Inclusions were performed 
from 1 February 2019 to 22 January 2020. Mean age was 76 years and 57% were women.  
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5.4.1 Indications for CSCI 
The most common indications for transition to CSCI were difficulty swallowing tablets at 
end of life, and to improve pain control when oral medication was considered to be having an 
insufficient effect. In two thirds of the patients the pain mechanisms were assessed as mixed 
neuropathic and nociceptive.  
5.4.2 The main study group 
The forty-seven patients who survived for three days or more after the initiation of CSCI 
were selected as the main study group to study the effects and adverse effects of the analgesic 
regime. This cohort included patients receiving low-dose midazolam for anxiety, but not for 
sedation. The median survival in this cohort was 5 days (mean 9).  
The subgroup of patients in this group who were prescribed methadone by CSCI were also 
studied separately.  
5.4.3 Analgesics and analgesic effect 
At the time of initiation of CSCI, patients used a mean of 1.7 non-opioid/adjuvant analgesics 
such as steroids, COX inhibitors, antidepressants or gabapentinoids. All were prescribed 
opioids: oxycodone (61%), morphine (23%), fentanyl patches (14%) and hydromorphone 
(2%). At initiation, the total median MEDD, excluding methadone, was 123 mg (IQR151) 
and after three days 150 mg (IQR 210). Improved pain control was seen after initiation of 
CSCI. In three days, the IPOS 5-point pain scores decreased, from a mean of 2.2 (median 2) 
to a mean of 1.5 (median 2) (p ≤ 0.001), and the proportion of patients judged to be 
overwhelmingly affected by pain decreased, from 45% to 19% (p ≤ 0.001).  
5.4.4 Adverse effects 
The patients were nearing end of life and levels of alertness decreased significantly over time, 
while the doses of sedative midazolam and performance status did not change significantly. 
At initiation of CSCI, 30% of the patients were judged to have delirium and 52% anxiety. 
The proportion with delirium did not change significantly, neither for patients younger nor 
older than 75 years of age, while the proportion with anxiety was halved (p < 0.05). Local 
erythema occurred around the SC needle in three patients, of whom one was prescribed 
methadone. All three had had the needle for at least five days and the erythema disappeared 




5.4.5 Patients receiving methadone 
Thirteen patients were prescribed methadone as add-on to another opioid in CSCI (MET) and 
their characteristics differed from those who did not receive methadone in CSCI (NMET): the 
median survival time from the initiation of CSCI was 14 versus 4 days (p = 0.044), initial 
median MEDD of opioids was 240 mg versus 113 mg (p = 0.004), and severe/overwhelming 
pain was seen in 77% versus 32% (p = 0.009) in the MET and NMET groups, respectively. 
Alertness decreased significantly in both groups over time. Otherwise, no significant 
differences were seen between MET and NMET regarding doses of midazolam, performance 
status, anxiety, or prevalence of delirium. 
The median daily dose of methadone was unchanged at 5 mg (IQR 5).  
One patient had an episode with respiratory ratio < 8 breaths/min, that passed without any 






In this thesis, I have focused on the use of low-dose methadone as an add-on to another 
ongoing opioid therapy to relieve complex cancer pain in dying patients. In our studies, we 
examined how low-dose methadone was used clinically and we assessed its effects and 
adverse effects. Further, we investigated to what extent, and how, methadone was used in 
specialized palliative care in Sweden today, including its use in continuous subcutaneous 
infusions with ambulatory infusion pumps for the most severely ill patients at the absolute 
end of life. In order to deepen the knowledge concerning the attitudes and opinions regarding 
methadone, in particular as a low-dose add-on, and to identify future areas in need of further 
research, we also, as a complement to the quantitative studies, conducted semi-structured 
interviews with physicians in specialized palliative and pain care in Sweden. The following 
discussion first presents the overall findings and interpretations, then clinical implications, 
and, finally, the methodological aspects. 
6.1 FINDINGS AND INTERPRETATIONS 
6.1.1 Indications for low-dose add-on methadone in specialized palliative 
care  
The subjects of primary interest in our studies were some of the most severely ill people in 
society: patients dying from advanced cancer with complex pain not responding adequately to 
commonly used analgesic methods. In such circumstances, physicians then do their best to 
find new treatment options. Possibly based on knowledge of methadone's partly unique 
pharmacological properties and anecdotal evidence, there has in recent years been a growing 
interest among physicians in specialized palliative care to use methadone for complex cancer-
related pain.  
Methadone is an opioid that, in itself, when referring to its µ-receptor effect, does not provide 
better pain relief than other opioids in common cancer-pain situations where a low dose of 
opioid, e.g. morphine, is already enough to achieve good analgesia [71, 73, 148]. For the vast 
majority of patients with cancer-related pain, strong opioids provide satisfactory analgesia.  
Unfortunately, regular opioids are not sufficient in all situations. In certain types of pain, 
additional analgesic therapy may be needed, for example in case of severe mixed nociceptive 
and neuropathic pain or in situations where opioid doses have needed to be increased rapidly 
without providing much better pain relief. These are situations where central sensitization of 
the nervous system can be suspected to be a contributing factor to the complexity of the pain.  
 
48 
Central sensitization is, at least partly, related to activation of NMDA receptors and leads to 
reduced thresholds (allodynia), increased responsiveness and prolonged aftereffects to 
noxious stimuli (hyperalgesia) [30]. NMDA receptors also seem to be involved in the 
development of opioid tolerance [33]. In selected cases, drugs that inhibit NMDA receptors 
appear to be able to reduce the effects of central sensitization [149, 150]. The opioid 
methadone is sometimes successfully used in these situations. 
As an alternative to carrying out a full, and potentially complicated, conversion to methadone 
as the single opioid, a method introducing a low-dose add-on of methadone to the ongoing 
opioid therapy has been used. Interestingly, this method proved to be applied in several 
specialized palliative care units in Sweden. In Study II, we found that during 12 months of 
study time, methadone for pain was prescribed to 8.6% of the patients cared for in the 
participating specialized palliative care units. 
In Studies I, II and IV we could see that in 70-80% of the cases where the pain mechanisms 
had been assessed, the indication for introducing the regimen with low-dose add-on 
methadone to another opioid was either a complex pain with mixed nociceptive and 
neuropathic components that was difficult to manage, or a purely neuropathic pain. This 
finding was also supported in interviews with physicians in Study III, who described that 
these mixed types of pain, in addition to existential pain and death anxiety, are considered the 
most complex pains to treat in specialized palliative care, but that a low-dose add-on of 
methadone in these situations is considered a rapid and effective way to achieve a sometimes 
almost unexpectedly effective pain relief in a safe way. 
Previous studies have shown that 49-75% of patients who were prescribed low-dose add-on 
methadone for cancer-related pain achieved an improved pain control within one week to one 
month after initiation of the treatment  [122-124]. The patients we studied were relatively 
closer to the end of life and did also generally seem to be in a more severe pain situation at 
the time of methadone initiation. However, we obtained similar results: in Study I, 80% had 
achieved improved pain relief after one week and in Study II it was reported that as many as 
96% of the patients reached improved pain control after the introduction of methadone. In 
Study III, a recurring description by the informants was that about half of the patients who 
were prescribed low-dose add-on methadone also had an improved analgesic effect, 
sometimes even described as an unexpectedly good effect. 
It is not fully clear why we observed such relatively high proportions of successful treatment 




and IV, were descriptive and not designed to answer the question of which patients benefited 
the most from methadone. 
However, one partial explanation may be that successful treatment is largely dependent on 
the initial selection of patients who are offered the treatment. The fact that we had a larger 
proportion of patients who were reported to have had an improved analgesic effect in our 
studies than what was previously reported, may be due to the fact that we did not focus solely 
on pain intensity, i.e. "severe pain". The main focus was on pain analysis and pain 
mechanisms. 
This became clearer in the interviews in Study III where the physicians described that the 
pain conditions that responded best to methadone tended to have been present for a longer 
time period and did not respond well to increased opioid doses. The informants used 
explanatory models in which concepts such as "central sensitization", "exhausted pain 
system" and "opioid tolerance" were mentioned as possible underlying mechanisms. They 
also gave examples of locations where these pains often occurred, such as pain arising from 
skeletal metastases or pathological fractures and pain from the spine or pelvis. The specific 
cancer diagnoses mentioned were prostate, breast, kidney, pancreas, and sarcoma. Just over 
half of the patients in Study I had at least one of these cancer diagnoses. To the best of our 
knowledge, except for the occurrence of severe pain [123], there are no previous descriptions 
of which patients could potentially benefit most from low-dose add-on methadone. 
Laboratory tests have previously shown a synergistic analgesic effect between methadone 
and morphine, but only an additive analgesic effect in combination with fentanyl or 
oxycodone [43]. Despite this, no clear pattern was seen in how strong opioids were combined 
with methadone in any of the present studies. The two most common regular drugs combined 
with methadone were: in Study I oxycodone and morphine, in Study II fentanyl and 
oxycodone and in Study IV hydromorphone and oxycodone. In Study II, it was reported that 
74% of the prescriptions of low-dose add-on methadone were made due to insufficient pain 
control from the ongoing treatment with a strong opioid. Since better pain control was 
reported to be achieved after initiation of low doses of methadone, a possible explanation 
could be that  the additional analgesic effect was to a certain extent due to the NMDA 
receptor inhibitory properties of methadone. 
In Study III, the emergence of central sensitization was mentioned as a possible underlying 
explanation to more complex pain. Drugs with an NMDA inhibitory effect, such as ketamine 
or 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP), can reduce the effects of 
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central sensitization and contribute to better pain relief in intractable chronic pain, although 
the evidence in cancer pain is not unequivocal, partly due to difficulties in studying these 
patients [149-152]. It also appears that the administration of ketamine over a short period of 
time improves analgesia more effectively than lower doses for longer durations [150]. This is 
of course of uncertain significance for methadone, but in addition to its µ-receptor inhibitory 
effect, methadone also has an NMDA receptor inhibitory effect [31, 58, 60]. By fine tuning 
the NMDA receptor subunits, neurons seem to be able to alter the functional properties of 
neuronal receptors [34]. Subtype-specific agonists for NMDA receptor glycine binding sites 
could be a possible, but so far not established, explanation behind the differing effects 
between different NMDA-inhibiting drugs [153].   
The addition of methadone to an ongoing opioid therapy has been associated with lower 
escalation rates or even decreased doses of opioid [1]. This was partially seen in our studies, 
as well. In Study I, there was a 14% reduction of MEDD after one week and in Study II an 
8% increase after a median of 21 days. In Study IV, there was a 25% increase of MEDD over 
three days, which may possibly be explained by these patients being in an imminently dying 
state. These were patients with severe pain, indicated by their generally high doses of opioids 
and, so far, the methadone treatment had only lasted a few days. 
Based on previous knowledge and our findings it is therefore not unreasonable to assume that 
methadone can also affect a condition with central sensitization. How long the effect of add-
on low-dose methadone lasts is unclear and, in the sparse literature available, the effect has 
been described as lasting for anywhere between a week up to at least several months [122-
124]. Also, in our qualitative Study III, some informants described that improved pain relief 
could exist for weeks to months after initiation of low-dose add-on methadone, even possibly 
after the add-on with methadone had ended and only the original opioid remained.  
One way to exemplify this could be to compare it with a situation where an ongoing analgesic 
treatment with methadone as the sole opioid, not low-dose add-on, was suddenly stopped. 
The pain would then return quickly. Thus, a possible explanation for why increased pain is 
not seen when a successful low-dose add-on methadone therapy is discontinued may be that it 
is due to the NMDA inhibitory effect that the low-dose add-on methadone primarily 
contributed to, resulting in a decreased central sensitization and “wind-down”. Once 
analgesic control is achieved, the goal is reached.  
The age distribution in Studies I, II and IV was a consistently mean 68 years for the patients 




were 74 and 78 years in Studies II and IV, respectively. In both studies, the age difference 
was significant (p < 0.001 and p < 0.05, respectively). The gender distribution was more 
varied. In Studies II and IV, about 40% were women and, in Study I, 64%. Previous studies 
on low-dose add-on methadone have not described groups both with or without methadone 
treatment in the same way as in our Studies II and IV, but in Wallace et al. patients prescribed 
low-dose add-on methadone were a mean of 63 years of age and 75% were women [122]. 
Similarly, in Courtemanche et al. the mean age was 60 years and 42% were women [123]. 
The underlying reasons behind, and the clinical significance of, these differences are not 
evident based on current knowledge.  
These studies provide pieces of the puzzle to be placed into the larger picture. It is still not 
certain whether methadone has a better analgesic effect than other opioids, as our studies 
were not designed to answer this particular research question. Despite this, it is likely that the 
mechanisms behind complex pain are the most important to address first. The adequate drug 
is then selected based on the pain mechanism. In the context of very seriously ill patients with 
severe cancer-related pain, NMDA receptor inhibition with methadone is an attractive 
alternative, especially in the form of low-dose add-on to another ongoing opioid. It appears to 
be an easy and safe way to initiate and use methadone, even in homecare, provided that there 
is a good level of knowledge and experience and good follow-up. 
6.1.2 Attitudes, opinions and perceptions 
In general, people's attitudes towards methadone used for analgesia is an unexplored area. 
Methadone maintenance therapy is known to be associated with opioid use disorder [83]. 
This can be both socially stigmatizing and adversely affect the use of methadone in 
specialized palliative care [83]. An important conclusion from Study III was that the 
interviewed physicians had not perceived that negative attitudes towards methadone were a 
problem, neither among physicians, staff, patients nor their relatives, and that the sparse 
negative attitudes did not preclude an analgesic use of methadone. Rather, there was an 
almost surprisingly positive attitude. Low-dose methadone treatment was reported by 
palliative care physicians to be a valuable, easier, and safer method to take advantage of 
methadone's special analgesic properties. 
6.1.3 Adverse effects and safety aspects 
In Study III, the interviewed physicians emphasized, more than anything else, that the risk of 
opioid overdose is considered the greatest risk of using methadone for pain. Although the µ-
receptor mediated inhibitory effect on pain comes quickly, within hours, it may take several 
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days before the full effect of NMDA receptor inhibition occurs. Pain effectively stimulates 
the respiratory center of the brain [79, 80]. This means that in patients with pain, opioid doses 
can often be increased significantly even in those with not very opioid-sensitive pain, without 
entailing a greater risk of respiratory depression. If, on the other hand, the pain subsides 
suddenly, such as when an NMDA inhibitory effect sets in, then the stimulation of the 
respiratory center ceases and the risk of sudden respiratory depression occurs. It is worth 
noting that despite the prevalent concern, no severe respiratory depression due to opioid 
overdose was reported in any of the Studies I-IV, possibly, because the Swedish palliative 
care community has learned to reduce the total daily dose of the primary opioid after a few 
days if an analgesic effect is seen with the add-on therapy. 
Opioids have certain µ-receptor-related adverse effects as a class and methadone is no 
exception. In all four studies, typical opioid-adverse effects were described as the most 
common, although in Study II it was shown that 80% of the patients were not judged to have 
any significant adverse effects at all. Examples of opioid-related adverse effects are 
constipation, delirium, sedation, nausea, hypotension, miosis, and respiratory depression. 
Mild adverse effects can often be prevented, for example with antiemetics, laxatives, etc. [65, 
67, 71, 72, 77]. 
The results are somewhat scattered regarding the prevalence of sedation and delirium in 
methadone treatment. In Studies I and IV, an increased incidence of sedation was noted seven 
and three days after methadone initiation, respectively, while in Study II, a lower proportion 
of patients with sedation was seen than in both Study I and other previous studies [123]. 
Perhaps because of the accepted strategy to reduce the primary opioid after two to three days. 
Study I showed that sedation, as expected, was more common in patients with a short 
remaining survival time.  
Delirium was also more common near the end of life in the patients with per oral methadone  
in Study I, while the patients who received methadone via CSCI in Study IV did not have an 
altered incidence of delirium, even regardless of age. This is an interesting finding that 
strengthens the idea that drug administration via CSCI at the end of life, even to elderly 
patients, is beneficial for symptom relief. No unequivocal conclusion can be drawn from this 
material as to whether methadone contributes to more or less sedation and delirium than other 
opioids. Other factors, such as proximity to the end of life, are probably of importance. 
There is a risk of cardiac arrhythmias due to QTc prolongation in cancer patients in general, 




least 30 mg are considered to increase the risk of negative QTc effects [89-95, 97]. This 
means that low-dose add-ons for patients in palliative care, usually around 5-20 mg daily, 
appear to be a safer alternative than higher doses. The benefit of this treatment can be 
considered to outweigh the risks and a possible explanation as to why ECG monitoring is not 
generally recommended in palliative care [97, 100, 101]. 
6.1.4 The practical use of low-dose add-on methadone in specialized 
palliative care 
The required frequency of methadone dosing varies significantly depending on the desired 
effect. If methadone is used as a primary opioid, a my-receptor effect is sought, and higher 
doses are needed. Dosing of 10 mg tablets up to every four to five hours during the first days 
may be required, usually followed by three times daily [69]. Previous reporting has described 
how there was no significant difference in analgesic effect during the first few days, whether 
morphine or methadone was administered, while there was a marked difference in long-term 
treatment [69, 70].   
Study III was important because, even though we already examined doses and administration 
with the questionnaire in Study II, we wanted to be more confident that we covered all the 
aspects, not least so as to be able to design future studies. According to the physicians in 
Study III, they prescribed low-dose add-on methadone to ongoing opioid treatment primarily 
for the purpose of achieving NMDA receptor inhibition, i.e., to reduce an increasing opioid 
tolerance or to remedy a condition with central sensitization. The practical aspects of 
achieving this were mainly concerned with how to start the treatment and then how to 
prescribe and follow-up to minimize the risks of serious adverse effects, in particular, severe 
respiratory depression. In Study II, as many as 96% of the patients who received methadone 
in specialized palliative care in Sweden did so in the form of a low-dose add-on. In earlier 
studies the initial doses of methadone added to an ongoing opioid varied between 1-10 mg 
daily, usually b.i.d. [120-124]. In our Studies I, II and IV, the median starting dose, and also 
the reported starting dose in Study III, was consistently 5 mg daily, most often as 2.5 mg 
twice daily. In case of insufficient analgesic effect, the dose was increased after about two to 
seven days to 5 mg b.i.d., and rarely to more than 10 mg twice daily, as reported in Studies I-
III. Thus, a starting dose of 2.5-5 mg during the first 24 hours should be considered an 
appropriate dose as a balance between the desired rapid effect and the need to minimize the 




Courtemanche et al. described that further increasing the methadone dose to patients who had 
responded with analgesia within a week from initiation, did not result in further pain 
reduction [123]. Methadone doses in our studies most often remained unchanged over time 
after the initial increases. This, together with the stable or even decreased doses of other 
regular opioids after methadone initiation, given how severely ill the patients were, makes the 
properties of methadone even more interesting.  
If the initiation of low-dose methadone resulted in the intended effect, the improved analgesia 
came within hours or a day. The informants in Study III described how they then first used to 
see an improvement in pain, and then sometimes a delayed cognitive impairment and later 
sedation. Being aware of this order in the onset of adverse effects, it was a well-established 
perception among experienced palliative physicians that it was often necessary to reduce the 
regular opioid dose, by about 25-30% to reduce the risk of opioid overdose when analgesia 
occurred. There were descriptions of situations where methadone was initiated in patients 
whose pain, up to that time, had not responded very well to opioid treatment. In some cases, 
the pain then seemed to subside rapidly followed by relatively rapid subsequent symptoms of 
opioid overdose. This was reported as the main reason why the physicians often chose to start 
with doses as low as 2.5 mg x 2 in the first few days. 
As reported in Study II and by some informants in Study III, it can be stated that initiation 
and use of low-dose methadone is done routinely in outpatient palliative care and is 
appreciated by the patients as it means that they do not have to be admitted to hospital to 
benefit from methadone treatment for pain. 
Overall, our studies support the conclusions of the American Academy of Hospice and 
Palliative Medicine from 2018, that safety of methadone is well established in cancer pain 
management [154]. Low-dose add-on to another opioid appears to be a safe method of 
offering the benefits of methadone while minimizing the risk of potential adverse effects, 
even in home care. Still, methadone prescription should be carried out by experienced pain 
and palliative care providers with careful dose titration and clinical monitoring, considering 
the individual patient´s total situation [154].  
6.1.5 Low-dose add-on methadone in the imminently dying patient 
In the imminently dying patient the oral route may be unreliable due to a reduced ability to 
swallow and absorb drugs. In the patients prescribed methadone in Study II, it was reported to 
be used in 86% of cases until end of life, and during the last 24 hours parenterally in at least 




parenteral preparation. Only 0.5% were reported as receiving methadone via continuous SC 
or IV infusion. In Study III, the physicians described how intermittent injections of 
methadone could be successfully given twice daily, but some also described how they were 
uncertain about possible adverse effects, e.g., sedation if methadone were to be given as 
CSCI. Several informants mentioned that they would like to use methadone in CSCI if they 
knew more. Others described CSCI containing methadone as both effective and 
complication-free. Altogether, these findings led to the setup of Study IV aimed at further 
exploring the use of low-dose add-on methadone via CSCI at the end of life.  
In the dying patient, continuous opioid infusion is beneficial in terms of both analgesic effect 
and avoidance of peaks and troughs in serum concentration [155-157]. Also, opioids and 
benzodiazepines in adequate doses via CSCI do not shorten life [156, 158, 159]. In Study IV, 
in addition to CSCI providing good pain control without increasing delirium, we also found 
that low-dose add-on methadone was successfully used in patients with severe pain and 
already on high doses of strong opioids, without an increase of adverse symptoms or any 
serious adverse effects that required special treatment. Thus, there are good reasons to use 
CSCI in dying patients and, if necessary, include low-dose add-on methadone.  
The marginally longer survival of the patients who received add-on low-dose methadone in 
CSCI, as described in Study IV, was notable. However, it was probably due to the patient’s 
severe illness with increased pain that resulted in an earlier CSCI prescription. Unpublished 
data from Study I showed similar results between our unmatched groups: a median survival 
of 13 days for all patients on the ward, and 28 days for those who were prescribed a low-dose 
add-on of methadone.  
An additional explanation for the overall relatively sparse use of methadone in CSCI, as 
indicated in Study II, may be the risk of skin adverse effects, such as SC erythema [102]. 
Erythemas are uncommon at SC injections of methadone 10 mg/ml in volumes < 2.5-3 ml per 
day [154, 160]. They usually fade away rapidly with rotation of the injection site [103-105, 
160]. The few adverse effects seen at the SC injection site in Study IV were all judged to be 
due to the fact that at least five days had passed since the last rotation of the injection site, 
rather than the methadone infusion itself. Thus, low-dose add-on methadone in CSCI should 
not be withheld from patients because of fear of dermal adverse effects. 
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6.2 CLINICAL IMPLICATIONS   
In specialized palliative care in Sweden, a low-dose add-on of methadone to another opioid 
seems to be an established treatment that is appreciated and regularly used mainly by 
specialists in palliative medicine, even for patients in palliative home care. 
Low-dose add-on methadone may be considered in situations with complex cancer-related 
pain of long duration involving central sensitization, or in situations with a rapid escalation of 
opioid doses. According to the clinical experience expressed by the clinicians in Study III, the 
greatest probability of successful treatment seemed to be in bone pain from metastases and 
pathologic fractures in the spine or cancer-related pain from the pelvis. Specific diagnoses 
were metastatic cancer of the prostate, breast, kidney and peritoneal carcinosis, as well as 
pancreatic cancer and sarcomas.  
The evidence for low-dose add-on methadone in complex cancer-related pain is still limited. 
It is therefore not possible to issue unambiguous clinical recommendations for how this 
treatment method should be used. On the other hand, based on both the literature and the 
results in Studies I-IV, it is possible to describe how the practical application in specialized 
palliative care in Sweden appeared, mainly according to the specialist physicians in Study III. 
In this way, everyone can draw their own conclusions about how this treatment model can be 
used. 
The indications for treatment were reported to be either need for improved pain control in 
complex cancer-related pain or marked development of opioid tolerance. It was important to 
minimize the risk of undiagnosed opioid overdose, both for patients who were cared for in 
specialized palliative care units and in home care. More severe adverse effects in the form of 
cognitive effects, sedation or impaired breathing were reported to occur usually within 2-4 
days after initiation or dose increase of add-on methadone. However, due to the long half-life, 
adverse effects could occur much later, especially if no dose reduction of the regular opioid 
was done when the patient began to experience improved pain relief. 
A common starting dose for low-dose add-on peroral methadone was 2.5 mg x 2. In complete 
absence of effect, the responsible physician could consider prescribing a first dose increase 
after 3-4 days and in case of partial effect, the dose could be increased after 5-7 days. 
Especially in home care, for safety reasons, it was common to wait up to seven days before 
considering a dose increase, depending on the treatment response. Dose increases were 
usually done in steps of 5 mg per day to a maximum of 10 mg twice daily. After every dose 




Daily follow-ups were usually performed by either a registered nurse or physician, both after 
initiation and after every dose increase. Follow-up in home care was often in the form of 
home visits but if there were cognitively intact relatives in the patient’s home, a telephone 
call could sometimes replace personal visits. If there was improved analgesia, a further dose 
increase of methadone was postponed and the responsible physician considered a dose 
reduction, usually with about 25-30% of the regular opioid, to avoid adverse effects.  
6.3 METHODOLOGICAL CONSIDERATIONS 
6.3.1 Internal validity 
Internal validity means how well a study measures what it is intended to measure, i.e., 
absence of systematic errors. The systematic errors remain the same regardless of sample 
size, as opposed to random errors which decrease by increasing sample size. There is high 
internal validity if there is a low risk of systematic errors that affect the results. Three main 
groups of systematic errors, or bias, are usually described: selection bias, information bias 
and confounding [161]. Studies I, II and IV were descriptive and did not use sampling but 
aimed at total cohorts.  
Selection bias 
Selection bias is referred to as the error introduced when the study population does not 
correspond to the non-study population, that is the participants are not representative of the 
whole target population. In cohort studies, selection bias means that the exposed and 
unexposed group are different in another way than the exposure being studied. Selection bias 
is a systematic error that occurs during recruitment or when deciding which patients are to 
stay in the study [161, 162].  
Study I was a total cohort including all patients introduced on an oral dose of methadone 
during the study period identified from medical records and, in principle, all eligible patients 
were likely included. However, it was likely that the patients from the very beginning had in 
some way been selected by their physicians to be prescribed low-dose add-on methadone. 
To the total cohort in Study II, all specialized palliative care units in Sweden affiliated to the 
Swedish Register for Palliative Care were invited to the 12-month survey and 45% chose to 
participate, possibly units already experienced with methadone and possibly with a relatively 
positive attitude to methadone. In participating units, completion of the questionnaire was 
mandatory in patients using methadone, reducing selection.  
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Selection bias can occur in registers if some groups are registered less often than others. The 
SRPC has a coverage rate of 90-100% in specialized palliative care and is cross-checked 
weekly with the Swedish Tax Agency's population register and annually with The National 
Cause of Death Register which, together, entails a low degree of selection and errors among 
the registered subjects [125]. 
Study III was a qualitative study, and no statistics were performed. A max variation sampling 
was aimed at. All physicians invited to be interviewed participated as informants. 
Study IV was a total cohort, but for organizational reasons inclusion was limited to daytime. 
In addition, imminently dying patients were studied and less than a third of eligible patients 
were eventually included. Of patients not included, nine out of ten was due to difficulty in 
giving informed consent and because of gatekeeping, where staff were especially prone to 
withhold certain patients for psychological, rather than medical reasons. In one tenth, the 
patients abstained. These factors introduce selection and affect the internal validity. 
Methadone was found to be prescribed to patients with the most severe pain, also affecting 
selection in this group.  
Information bias 
Information bias, or misclassification bias, means a systematic error in the measurement or 
classification of the participants in the study. This can occur when the information collected 
differs for different participants [161, 162]. Participants in a cohort study that are excluded 
due to loss to follow-up are one example.  
It is difficult for patients to estimate symptoms during the last weeks of life, mainly due to 
debilitation, delirium and lowered levels of consciousness [16]. This needed to be addressed 
in the studies as there were generally, at least for research purposes, consequently insufficient 
systematic assessments of pain and adverse effects in the medical records. In Study I, a 
predefined protocol was used to assess pain and adverse effects. The medical records were 
reviewed by two physicians individually, who also followed-up and discussed until they 
agreed on all assessments. The questionnaire in Study II was pilot-tested in one palliative care 
unit before it was launched in the main study. In Study II, the registered nurse or the 
responsible physician completed both the SPRC’s ELQ and the methadone survey after the 
death of each individual patient. As far as possible, the information provided was based on 
patient reported outcomes, but was otherwise up to the individual physician or registered 
nurse to reproduce as accurately as possible, based on the team's opinion and documentation 




systematic symptom assessments in the medical records is due to the nature of the matter: the 
scales usually presuppose intact cognition and full alertness in the patients, not so often seen 
in end of life care. However, VAS/NRS, ESAS or IPOS was used for pain evaluation in 84% 
of patients and validated tools for assessment of symptoms in 50%.    
In Study IV, the patients were so seriously ill that validated observer ratings had to be used. 
Even if observer ratings do not directly reflect the patients' experiences, they still enable 
studies in acutely dying patients during their very last days of life [163]. Both Studies I and 
IV were performed at Stockholm Sjukhem palliative care department and primarily reflect the 
experiences in this environment. 
Confounding 
Confounding means "confusion of effects", that is, finding a connection, but for the wrong 
reason, and can occur when the cause of a particular treatment is also a prognostic factor for 
the study results. A confounder is thus a factor that disturbs both the exposure and the result 
but is not a causal factor. Randomization and matching can prevent confounding. Statistical 
analysis can also adjust for confounders [161, 162].  
In all four studies, the most important confounder was probably that patients were close to the 
end of life, in many cases in the terminal dying phase. In Study I, we tried to get around this 
in part by describing the occurrence of delirium and sedation separately for patients with 
more or less than 14 days survival. In Studies I, II and IV we lacked the opportunity to 
correct for the influence of social, psychological or existential factors that also affect human 
behavior [164, 165]. Another confounder is the µ-receptor mediated analgesic effect common 
to all opioids. 
6.3.2 Random errors and precision 
Random errors are the influence of chance. Random errors are tested with significance 
analysis and described with p-values. The p-value indicates the probability that the null 
hypothesis, which assumes that there is no difference between the groups, is rejected even 
though it is true. In medical research, a p-value of < 0.05 is often used as a significant level. 
However, other possible levels can be used, such as < 0.01 or < 0.001 [162].  
In our studies, p-values were used to describe the degree of assertiveness in indicating 
differences after statistical analysis that compared dependent or independent groups. 
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6.3.3 Assessments of symptoms 
In the four studies, treatment of complex pain was studied in individuals who are in the final 
stages of life due to a serious illness. This poses already well-known methodological 
challenges when patients' opportunities to actively participate in data collection are rapidly 
limited when the deterioration occurs [16].  
To enable the study of even the most severely ill individuals, various methods have been used 
to circumvent and minimize the need for patient participation. In Study I, the medical records 
from deceased patients were assessed in a systematic way by two physicians individually, 
who also compared their results and reasoned until consensus was reached. Study II benefited 
from the good coverage rate in the SRPC and healthcare professionals reporting their 
assessments of dying patients' last days. In Study III, physicians in specialized palliative care 
were interviewed about their own perceptions, but also about the perceptions of other staff, 
patients, and their relatives. Finally, in Study IV, validated questionnaires were used for 
proxy estimates performed by registered nurses. This ensured continuity even in the absolute 
final stages of life.  
6.3.4 External validity 
In a quantitative method, external validity means whether the results from a study can be 
generalized to another population [162]. 
Studies I, II and IV describe total cohorts. The results from these studies can be used to plan 
future prospective studies involving patients in specialized palliative care. Another way of 
generalizing the results from Studies I, II and IV can be inspired by qualitative research: the 
reader can, by comparing the described conditions for each study, e.g., demographic and 
healthcare data, draw conclusions as to how the study results can be interpreted and applied 
in their own context. 
6.3.5 Trustworthiness 
In qualitative research, the term trustworthiness is used in much the same way as validity and 
reliability in quantitative research. Trustworthiness is thus about whether the results of the 
study can be trusted and used. The three terms commonly used for trustworthiness are 
credibility, dependability and transferability [134], which is applicable to the qualitative 







Credibility is about how well the data and analysis really address what was intended to 
investigate [134]. 
The purpose of the study was to explore both positive and negative attitudes as well as 
opinions and practical aspects regarding the use of methadone in specialized palliative care in 
Sweden. To capture as many aspects as possible, the informants were selected through 
purposeful maximum variation sampling, mainly regarding age, gender, geographical 
representation, level of education and experience of palliative medicine or pain medicine. The 
number of informants was limited by when additional interviews did not appear to contribute 
any additional new essential information, often described with the term saturation and judged 
to be reached approximately after 15-20 interviews. Another 10 interviews were conducted 
however to ensure, as far as possible, that no new valuable information was found.  
Dependability 
Dependability is how much both the data collection and the researcher's decision change 
during the analysis process [134]. Through interviews and observations, the researcher 
continuously gains new insights into the phenomenon being studied. This in turn can affect 
both the focus and follow-up questions.  
The interview guide was pilot tested on two participants. Open-ended questions with 
appropriate follow-up questions were asked and additional questions were also added. When 
new areas of interest were discovered, they were also explored. During the interviews, similar 
questions were asked several times in different ways in order to better ensure that different 
aspects had been sufficiently elucidated and discussed. 
We described the different steps and nomenclature used during the analysis, which was 
performed according to Hsieh [128]. To name the meaning units, the exact words from the 
interviews were used as short codes, so as not to lose any important meaning. The researchers 
also analyzed relevant parts of the interviews and compared the results. In a blinded sample 
control comprising 30 citations, the supervising researcher chose the same code as the first 
researcher in as many as 97% of the cases, even though the supervising researcher also had 
double-coded 17% of the longer citations. The final categories were discussed among the 
researchers and revised to find common formulations, rather than a consensus. To enable 
readers to assess similarities and differences and to illustrate the categories, representative 
quotes from the text were presented. During the analysis for Study IV, the most obvious and 
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common themes were attitudes, indications, practical use, and refractory pain situations 
which thus formed the basis for the analysis and reporting. 
Transferability 
Transferability means the extent to which the results of a qualitative study can be applied 
outside the study and is similar to the concept of external validity used in quantitative 
research [134]. It is up to the reader to transfer the results to another context. 
To enable an assessment of transferability in Study III, we described the research team, 







The following conclusions can be drawn from the studies included in this thesis: 
• A considerable proportion of patients with complex cancer-related pain at the end-of-life 
who received add-on low-dose methadone in combination with another ongoing opioid 
treatment seemed to experience rapidly decreasing pain. 
• Low-dose methadone treatment was reported by palliative care physicians to be a valuable, 
easy, and safe method to take advantage of methadone's special analgesic properties. 
• In specialized palliative care in Sweden, the addition of low-dose methadone to another 
ongoing opioid for cancer-related pain is an emerging treatment option that is appreciated and 
regularly used by, in particular, specialists in palliative medicine, even for patients in 
palliative home care. 
• Although methadone is sometimes associated with the treatment of substance use disorders, 
the informants reported that there were few negative attitudes among physicians, patients, or 
their relatives towards methadone use for pain treatment and that this did not constitute an 
obstacle to its acceptance.  
• According to the informants, low-dose methadone may contribute to improved pain relief in 
selected patients with certain diagnoses, especially in situations of complex pain involving 
central sensitization. 
• Continuous subcutaneous infusion of opioids is an effective way to reduce pain in the 
imminently dying patient without any increased adverse effects in the form of delirium or 
respiratory depression. 
• For complex cancer-related pain, low-dose methadone in combination with another opioid 





8 FUTURE RESEARCH 
Adding low-dose methadone to another ongoing opioid treatment may help to relieve pain in 
selected patients with severe and complex pain. However, so far, the research carried out on 
this subject, including this thesis, is primarily of an observational and descriptive nature. It is 
not yet possible to say that the excellence of low-dose add-on methadone has been 
established. In 2019, Chalker wrote in a review of the efficacy of low-dose and/or adjuvant 
methadone in palliative medicine that, although promising, the evidence base for adjunct 
methadone in populations with palliative care needs is limited and has methodological 
shortcomings [166]. Any recommendation in clinical practice should, therefore, be 
interpreted with caution. Thus, although potentially effective as an adjuvant, it will not be 
substantiated until further evidence arises [166]. 
An important future study should be a sufficiently powered, double-blinded randomized 
controlled study (RCT) comparing add-on low-dose methadone with the add-on of another 
low dose opioid, i.e. morphine, to selected patients with complex pain where the proposed 
NMDA-related mechanism is at least theoretically of importance. This would have the 
potential to provide further answers to what the real effect of methadone is when the µ-
receptor stimulating effect is excluded.  
A study that non-selectively included all patients with morphine-sensitive pain would carry 
some risk that any NMDA receptor-related effect would be more difficult to identify behind 
the opioids' common µ-receptor stimulating effect. Therefore, to increase the precision, the 
patient selection could be based on the preliminary findings from this thesis, in particular on 
the qualitative Study III that described the possible pain mechanisms, specific diagnoses and 
localizations that seemed to be the most susceptible to low-dose add-on methadone treatment.  
Additional topics that any future research could potentially address are:  
• Are there differences in the effect of low-dose add-on methadone depending on the 
mechanism and duration of pain and on the cancer diagnosis?  
• How long does the presumed effect of add-on methadone last? After how long could 
the add-on treatment be discontinued, and the patient still benefit from a continued 
analgesic effect?  
• If an NMDA receptor inhibitory effect of methadone is desired, is dosing twice or 





9 POPULÄRVETENSKAPLIG SAMMANFATTNING  
Lågdos metadon som tilläggsbehandling till pågående opioidbehandling vid 
cancerrelaterad smärta  
9.1 BAKGRUND  
Smärta är vanligt vid långt gången cancersjukdom. Lyckligtvis har smärtbehandlingarna 
förbättrats under senare år. För de flesta patienter som lider av avancerad cancersjukdom nära 
livets slut fungerar idag smärtlindringen bra. Man försöker alltid att skräddarsy 
smärtlindringen efter mekanismen som orsakar smärtan. Ibland kan det räcka med enkla 
preparat som paracetamol, naproxen eller ibuprofen, trots att man kanske har spridning till 
skelettet. Då väljer man det. Många behöver emellertid också behandling med 
morfingruppens preparat, det som kallas för starka opioider. Med hjälp av opioider blir de 
flesta smärtfria, utan att bli trötta av medicineringen.  
Tyvärr finns det en grupp patienter som inte blir smärtfria, ens med ganska höga 
morfindoser. Det kan bero på att man har flera smärtor samtidigt, med flera bakomliggande 
smärtmekanismer. Morfin och andra starka opioider som verkar via morfinreceptorn, det 
som heter µ-receptorn på vetenskapligt språk, fungerar vid många smärtmekanismer men 
inte alla.  
I vissa fall uppstår en komplex smärta som till exempel kan bero på att man, förutom den 
vanliga värken som beror på vävnadsskada, också har fått inslag av nervsmärta. Ett 
komplext smärttillstånd kan också bero på att det uppstått på grund av det som på 
vetenskapligt språk kallas för central sensitisering. Enkelt uttryckt innebär det att 
smärtsystemet blivit överkänsligt. Smärtimpulser som normalt skulle ha bromsats långt 
innan de nådde hjärnan och därmed långt innan man upplevde smärta, flödar nu fritt upp till 
hjärnan och ger svåra smärttillstånd, där morfin inte räcker till. Det beror på att det här 
flödet underlättas av att en viktig receptor, NMDA-receptorn, blivit aktiv. Om man kan 
hämma den receptorn, kan man också minska smärtan. 
Läkemedel som hämmar NMDA-receptorer verkar kunna minska sensitiseringen av 
nervsystemet och göra att smärtan blir mer känslig för morfin igen. Ett sådant läkemedel är 
metadon, ett läkemedel annars kanske mest är känt vid heroinavvänjning.  
Metadon verkar till en del smärtlindrande på samma sätt som morfin, men kan alltså också 
hämma NMDA-receptorer. Därför kan det hjälpa till att lindra komplex cancerrelaterad 
smärta. Metadon har också en del nackdelar, bland annat lång och varierande halveringstid i 
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kroppen som gör att det är svårstyrt. Det kan ta flera dagar eller veckor innan man når stabila 
koncentrationer i blodet. Den smärtstillande effekten blir svår att förutsäga. Metadon 
påverkar också många andra läkemedel. En del biverkningar, som till exempel 
andningsdepression, kan komma med fördröjning. Man behöver ha mycket erfarenhet för att 
ordinera metadon.  
Vid komplex cancerrelaterad smärta eller när vanliga opioider verkar ha tappat effekten, har 
erfarna läkare ibland prövat att byta opioid till just metadon. Man har förstås varit medveten 
om de risker som behandling med metadon kan medföra och ett annat sätt att använda 
metadon har därför kommit att prövas, särskilt inom specialiserad palliativ vård. Istället för 
att helt och hållet byta till metadon, har man istället lagt till en låg dos av metadon till den 
redan pågående opioidbehandlingen. Detta för att försöka dra nytta av metadonets unika 
smärtlindrande egenskaper och samtidigt minska risken för allvarliga biverkningar. 
Syftet med denna avhandling var att studera olika aspekter av tilläggsbehandling med låg dos 
av metadon till en annan pågående opioid, inom specialiserad palliativ vård i Sverige. Fyra 
studier har utförts. 
9.2 METODER OCH RESULTAT 
I studie I granskades journalerna för de 4233 patienter som vårdats i livets slutskede på 
Stockholm Sjukhems palliativa klinik under åren 2006–2013 och av dem hade 165 ordinerats 
metadon. Av dessa inkluderades de 80 patienter som ordinerats en låg dos av oralt metadon 
som tillägg till en pågående opioidbehandling mot komplex cancerrelaterad smärta. 
Fördjupad journalgranskning visade att 80 procent av patienterna bedömdes ha uppnått en 
signifikant bättre smärtkontroll inom en vecka efter att man hade lagt till låg dos av metadon. 
De biverkningar som sågs var inte andra än de man hade kunna vänta sig med vanligt morfin 
och inga allvarliga biverkningar registrerades.  
I studie II användes under 12 månader en tilläggsenkät till Svenska Palliativregistret där 
läkare och sjuksköterskor vid 60 specialiserade palliativa vårdenheter i hela Sverige 
rapporterade in data om 4780 avlidna patienter. Av dessa hade 410 (8,6%) ordinerats 
metadon, i 96% av fallen som lågdos i tillägg till annan opioid. Metadon användes i snitt i tre 
veckor (medianvärde) och i 86% av fallen till livets slut. Vanligaste orsaken var komplex 
cancerrelaterad smärta. Hela 94% av de patienter som ordinerades metadon rapporterades ha 




Studie III var en kvalitativ studie med syfte att undersöka olika attityder, åsikter, betydelse 
och praktiska aspekter kring användning av metadon för smärtlindring i livets slut. Semi-
strukturerade intervjuer genomfördes med 30 läkare som arbetade inom specialiserad palliativ 
vård eller smärtvård i Sverige. Intervjuerna skrevs ut och texterna analyserades med 
konventionell kvalitativ innehållsanalys.  
Det visade sig att, enligt läkarna, attityder eller åsikter inte utgjorde något hinder för 
användning av metadon mot smärta. Metadon rapporterades återkommande användas och 
fungera framför allt vid långdragen opioidanvändning med otillräcklig effekt och central 
sensitisering vid komplexa cancerrelaterade smärtor i ryggrad eller bäcken. Typiska 
diagnoser var skelettmetastaser av prostata-, bröst- eller njurcancer men även 
bukspottkörtelcancer eller sarkom.  
Läkarna beskrev hur de genom att starta med låga doser av metadon och sedan öka doserna 
stegvis, kunde få bra smärtlindrande effekt och samtidigt undvika allvarliga biverkningar, 
även vid användning i hemsjukvård. Om metadon började ge bra smärtlindrande effekt inom 
några dagar minskade de ofta dosen av den redan pågående opioiden med 25-30% för att 
minimera risken för opioidöverdosering. Den smärtlindrande effekten rapporterades sitta i 
åtminstone veckor eller månader och det var i de flesta fall tillräckligt inom specialiserad 
palliativ vård. En del läkare var närmast okritiskt positivt inställda till metadon, medan andra 
varnade för övertro på enskilda preparat och för risken att förbise andra 
behandlingsalternativ.   
I studie IV följdes de dagliga symtomen hos 93 döende patienter som behövde få sina 
symptomlindrande läkemedel tillförda kontinuerligt subkutant med hjälp av en 
läkemedelspump. Orsaken var oftast ökande svårigheter att svälja tabletter på grund av 
försämrat allmäntillstånd i livet slut eller behov av bättre smärtlindring. Överlevnaden var i 
snitt fyra dygn (medianvärde). Smärtlindringen förbättrades signifikant hos patienterna när 
den subkutana tillförseln startade utan att förekomsten av förvirring ökade, oavsett ålder. Låg 
dos av metadon användes även i en del av de subkutana läkemedelspumparna och man kunde 
se att det gavs framgångsrikt främst till patienter som från början bedömdes ha mycket svår 
smärta, utan att allvarliga biverkningar uppstod.  
Startdosen per dygn av metadon rapporterades i alla studier vara i median 5 mg, som ofta 
ökades till 10 mg och maximalt 20 mg, per dygn. Tilläggsbehandling med lågdos metadon 
gavs vanligen uppdelat på två doser per dygn. 
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9.3 DISKUSSION OCH SLUTSATSER 
Patienterna i dessa fyra studier var bland samhällets allra svårast sjuka; personer döende på 
grund av avancerad cancersjukdom med komplexa smärtor som inte lindras tillräckligt bra 
med de vanliga smärtstillande läkemedlen.   
I studie I-IV beskrevs att vissa patienter med svårbehandlad komplex cancerrelaterad smärta 
verkade kunna få förbättrad smärtlindring genom tillägg av en låg dos metadon till den opioid 
som de redan använde. Metoden användes återkommande inom specialiserad palliativ vård i 
Sverige, där nästan en tiondel av patienterna ordinerades metadon. Attityder till metadon 
verkade inte utgöra något hinder för dess användning. Genom att starta med låga doser och 
sedan öka stegvis med flera dagars intervall verkade metadon kunna introduceras på ett säkert 
vis. Kontinuerlig subkutan tillförsel av opioider, inklusive låg dos av metadon, kunde 
effektivt och säkert minska smärtan hos döende patienter utan ökad risk för förvirring, oavsett 
ålder.  
Sammantaget kan tilläggsbehandling med låg dos metadon betraktas som ett värdefullt 
verktyg för smärtlindring hos utvalda patienter med komplex cancerrelaterad smärta inom 
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12.1 APPENDIX I. SUPPLEMENTARY SURVEY TO THE SRPC’S ELQ  
(STUDY II) 
This methadone survey was filled in online and dealt with the following points: 
Fick patienten metadon ordinerat för smärtbehandling i någon form (inte för 
behandling av beroende) under tiden som din enhet hade ansvar för patienten? 
□ Ja – övriga metadonfrågor gås igenom □ Nej – hela enkäten är klar 
Varför ordinerades metadonbehandling mot smärta? 
□ Otillräcklig smärtlindring trots höga opioiddoser 
□ Otillräcklig smärtlindring trots höga opioiddoser i kombination med läkemedel mot 
neuropatisk smärta (t.ex. gabapentin, amitriptylin) 
□ Störande biverkningar av andra opioider 
□ För behandling av smärta som varit svårbehandlad på annat sätt 
□ Byte till metadon som enda opioid 
□ Primärbehandling mot neuropatisk smärtkomponent 
□ Annan anledning. Vilken? 
Bedömd huvudsaklig fysiologisk smärtmekanism  
□ Nociceptiv smärta □ Neuropatisk smärta 
□ Blandad nociceptiv och neuropatisk smärta □ Oklar smärtmekanism 
□ Smärtmekanismen ej bedömd 
Läkaren som initierade behandlingen med metadon är  
□ Icke-legitimerad läkare □ Legitimerad läkare □ ST-läkare □ Specialistläkare 
Läkaren som initierade insättningen av metadon har  
□ Stor erfarenhet av metadon □ Begränsad erfarenhet av metadon 
□ Ingen erfarenhet av metadon 
Skedde behandlingen i samråd med en eller flera andra läkare? 
□ Ja □ Nej  
Med vem skedde samrådet? 
□ Annan specialistläkare med palliativmedicinsk kompetens 
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□ Annan specialistläkare med smärtmedicinsk kompetens  
□ Annan specialistläkare 
Var gavs de första doserna av metadon? 
□ På specialiserad palliativ slutenvårdsavdelning 
□ På ordinarie sjukhusavdelning 
□ På kommunalt boende 
□ I specialiserad palliativ hemsjukvård 
□ I allmän hemsjukvård 
Datum då metadonbehandlingen startades 
Startdos (mg/dygn) 
Administrationssätt vid start 
□ Peroralt □ Subkutant □ Intravenöst 
Doseringstillfällen per dygn  
□ 1 □ 2 □ 3 
□ Gavs som kontinuerlig infusion □ Gavs enbart vid behov 
Har dygnsdosen av metadon ändrats under vårdtiden? 
□ Ja □ Nej  
Vid hur många tillfällen ändrades metadondosen under vårdtiden? 
Dygnsdos metadon under det sista dygnet som metadon administrerades (mg/dygn) 
Administrationssätt, sista dygnet  
□ Peroralt □ Subkutant □ Intravenöst 
Antal doseringstillfällen för metadon under det sista dygnet som metadon 
administrerades 
□ 1 □ 2 □ 3 □ Gavs som kontinuerlig infusion □ Gavs enbart vid behov 
Metadonbehandlingen avslutades 
□ I samband med dödsfallet □ Annat datum 
Datum då metadonbehandlingen avslutades 
Anledning till att metadonbehandlingen avbröts? 




Hade patienten någon annan samtidig opioidbehandling? 
□ Samtidig opioidbehandling första dygnet (ange substans och dygnsdos) 
□ Samtidig opioidbehandling vid behov sista dygnet (ange substans och sammanlagd 
dygnsdos) 
□ Ingen annan opioidbehandling än metadon 
Effekten av metadonbehandlingen på patientens smärta  
□ Mycket god □ God □ Måttlig □ Ingen alls 
Biverkningar relaterade till metadonbehandlingen 
□ Inga biverkningar □ Förstoppning □ Illamående □ Konfusion 
□ Sedering □ Andningspåverkan □ Fall □ Annan, vilken?  
Sammantaget, bedömer du att insättningen av metadon var till nytta för denna patient? 






12.2 APPENDIX II. SEMI-STRUCTURED INTERVIEW PROTOCOL (STUDY III) 
The questions below were only initial questions, with the possibility to follow-up 
questions, depending on the initial response. When needed, the questions were modified 
to suit the actual interview situation. 
Berätta om dig själv och din medicinska bakgrund. 
Berätta om din erfarenhet av att behandla smärta genom åren. 
Hur stor erfarenhet har du av att hantera svåra fall? Om du har det, hur mycket erfarenhet har 
du? Har du utvecklat några egna strategier (för komplex smärtbehandling)? 
Vilken erfarenhet har du av att använda metadon i smärtbehandling, om någon? Utveckla. 
Om du använder metadon, vad överväger du innan du sätter in det på en patient? 
Tycker du att du har tillräckliga kunskaper och erfarenhet för att förskriva metadon? Beskriv! 
Vilka smärtmekanismer anser du är de viktigaste för att välja metadon? 
Beskriv en patient som du skulle förvänta dig kan dra nytta av insättning av metadon mot 
smärta. 
När det gäller metadonanvändning: hur är den allmänna kunskapsnivån bland dina kollegor 
och hur använder de metadon, tycker du? 
Hur uppfattas metadon bland dina kollegor – finns positiva eller negativa attityder? 
Skulle du rekommendera en ny kollega att förskriva metadon? Varför eller varför inte? 
Hur ser kunskapen ut om metadon bland övrig personal? 
Beskriv eventuella förekommande fördomar om metadon som du har stött på [hos kollegor, 
personal, patienter eller deras närstående]. 
Kommer du ihåg något fall där metadonbehandling resulterade i en oväntat god 
smärtlindring? 
Kommer du ihåg något fall där metadonanvändning blev särskilt problematisk [oavsett 
orsak]? 
Slutligen, om eller när smärtlindring erhålls hos en patient med ett ovanligt svårt 





12.3 APPENDIX III. START PROTOCOL (STUDY IV) 
The start protocol referred to the patient's situation just before the CSCI was initiated. The 
start protocol was thus filled in only once. Every subsequent day thereafter, the daily protocol 
was filled in. The only difference between the start protocol and the daily protocol was the 
first page where the latter did not include the questions about indication for CSCI and type of 
pain. In the daily protocol, on the page with the pain drawing, was also to be marked each day 
























Plats för namnetikett 







Fullständigt ifyllt protokoll lämnas i 
låda märkt ”Pumpstudien – ifyllda 
protokoll”  
på avdelningens expedition 
Frågor? Kontakta Per Fürst 







□ Annan, nämligen: _____________________ 
2. Indikation för insättning av smärtpumpen 
 Sväljsvårigheter på grund av försämrat allmäntillstånd 
 Sväljsvårigheter av medicinska skäl, t.ex. stroke 
 Hinder i magtarmkanalen 
 Otillräcklig effekt av pågående smärtmedicinering 
 Biverkningar av pågående smärtmedicinering 
➢ Ange biverkan__________________ 
 Annat, nämligen________________________ 
4. Aktuell andningsfrekvens 
(andetag/minut) 
□ Hög >16  
□ Normal 12–16 
□ Sänkt <12  
□ Låg <8  
□ Patienten avstår 
□ Kan ej ge medgivande 
 
(OBS! Skriv ändå namn och 
personnr/etikett!) 
1. Lägg in att ”fylla i dagligt protokoll” i ”Att göra” i TakeCare 
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4. Smärta och hudirritation 
□ Markera med skuggning   ///////  ungefär var den mest besvärande smärtan 
funnits senaste dygnet 
□ Markera med ring  O var eventuella relevanta hudirritationer finns. Beskriv dem 
kort, skriv intill markeringen 
 









5. IPOS  
(fylls i av undersökaren med fokus på det senaste dygnet)  
 





F2. Vänligen markera den ruta som bäst beskriver hur patienten har påverkats av 











Smärta 0 1 2 3 4  
Andnöd 0 1 2 3 4  
Svaghet eller bristande 
energi 0 1 2 3 4  
Illamående 0 1 2 3 4  
Kräkningar 0 1 2 3 4  
Dålig aptit 0 1 2 3 4  
Förstoppning 0 1 2 3 4  
Ont eller torr i munnen 0 1 2 3 4  
Dåsighet 0 1 2 3 4  
Nedsatt rörlighet 0 1 2 3 4  
Eventuella andra symtom: 
 
1.____________________ 0 1 2 3 4  
2. ___________________ 
0 1 2 3 4  




















F3. Har han/hon känt 
ångest eller oro över sin 
sjukdom eller 
behandling? 
0 1 2 3 4  
F4. Har någon av 
hans/hennes närstående 
känt oro eller varit 
bekymrad för patienten? 
0 1 2 3 4  
F5. Anser du att 
patienten känt sig 
nedstämd? 
0 1 2 3 4  















F6. Anser du att han/hon 
känt lugn och ro 
inombords? 
0 1 2 3 4  
F7. Har patienten 
berättat för sina 
närstående hur han/hon 
mår? 
(i den utsträckning som 
han/hon önskat) 
0 1 2 3 4  
F8. Har patienten fått så 
mycket information som 
han/hon önskat? 
0 1 2 3 4  


























F9. Har han/hon fått 
hjälp med praktiska 
problem? 
(problem som 
uppkommit i samband 
med sjukdomen) 






6. Richmond Agitation-Sedation Scale (RASS) 

























7. Performance enligt ECOG - Allmäntillstånd 
 
Kryssa för bästa alternativet som beskriver senaste dygnet 
 
□ 0. Klarar all normal aktivitet utan begränsning 
□ 1. Klarar inte fysiskt krävande aktivitet men är uppegående och i stånd till 
lättare arbete. 
□ 2. Är uppegående och kan sköta sig själv men klarar inte att arbeta. Är uppe 
och i rörelse mer än 50 % av dygnets vakna timmar. 
□ 3. Kan endast delvis sköta sig själv. Är bunden till säng eller stol 
mer än 50 % av dygnets vakna timmar. 
□ 4. Klarar inte någonting. Kan inte sköta sig själv. Är bunden till säng eller stol. 









Mycket agiterad. Drar i eller drar ut tub/katetrar eller har ett 








+1 Rastlös. Ängslig eller orolig men ej aggressiva eller kraftfulla rörelser. 
 
□ 




Slö. Ej helt alert men upprätthåller (mer än 10 sekunder) vakenhet 




Lätt sederad. Kortvarig (mindre än 10 sekunder) vakenhet med 













-5 Ej väckbar. Ingen respons vid tilltal eller fysisk stimulering. 
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8. Confusion Assessment Method (CAM)  
(Bedömningen gäller senaste dygnet. Familjemedlem eller vårdpersonal utfrågas 
vanligtvis) 
1. Akut debut eller fluktuerande förlopp 
□ ja □ nej Finns det tecken på att en akut förändring skett i patientens mentala 
status i jämförelse med patientens normaltillstånd? 
 
□ ja □ nej Har det onormala beteendet fluktuerat, d.v.s. har det eventuellt varit 
helt borta, eller varierat i svårighetsgrad? 
 
2. Störning i uppmärksamhet 
□ ja □ nej Har den undersökta svårt att fästa uppmärksamheten, är han t.ex. lätt 
distraherad eller har han svårt att hålla sig till det som diskuteras? 
 
3. Splittrad tankeförmåga 
□ ja □ nej Är patientens tankar splittrade, osammanhängande, med t.ex. irrande 
eller irrelevant tal, är tankeflödet oklart eller ologiskt eller växlar 
konversationen oförutsägbart från en sak till en annan? 
 
4. Förändrad medvetandegrad 
□ ja □ nej Är patientens medvetandegrad annat än normal? Utvärdering av 
patientens medvetandegrad: normal, alert (överkänslig mot 
omgivningens stimuli), dåsig (lättväckt) eller medvetslös (kan inte 
väckas). 
 
-Slut- 
